

## Subject Index For Volume 29

- Ablation, renal, hypertension (abst) ..... 260
- ABP assay, diagnosis ..... 142
- ACE inhibitor
- enalaprilat (abst) ..... 243
- ramipril (abst) ..... 241
- sodium restrict (abst) ..... 254
- Acetate
- endothelium in (abst) ..... 215
- intolerance prediction (abst) ..... 215
- metabolism, acid-base (abst) ..... 227
- Acetazolamide
- ammoniogenesis (abst) ..... 354
- cell pH (abst) ..... 366
- Acetohydroxamic acid, stones (abst) ..... 170
- Acetylated alkyl phosphoglycerides, PAF ..... 469
- Acetylcholine
- decreased endothelium-dependent relaxations (abst) ... 256
- Acid
- cyclosporine stimulates secretion (abst) ..... 368
- regulation of renal secretion, distal nephron segments . 1099
- sulfated bile, inhibition of Na-H antiport (abst) ..... 1257
- Acid fast bacillus in dialysis (abst) ..... 230
- Acid-base
- balance, urea formation (abst) ..... 367
- disturbance, bicarbonate conductance to HCO<sub>3</sub><sup>-</sup> (abst) . 375
- disturbance, edema (abst) ..... 197
- metabolism after ischemia ..... 989
- respiratory during HD (abst) ..... 220
- status in HD (abst) ..... 227
- systemic effects, regulation of glutamine metabolism in
- dog ..... 68
- Acidemia
- systemic, chronic mineral acid feeding and pH. .... 667
- Acidification
- cellular, activates Na-H exchange and Na-K pump
- (abst) ..... 397
- clathrin-coated vesicle, by vanadate (abst) ..... 364
- metabolic alkalemia, IMCD (abst) ..... 363
- ureteral obstruction ..... 1167
- urinary, PTH (abst) ..... 363
- Acidosis
- acid-base metabolism after ischemia ..... 989
- anion gap, hemodialysis (abst) ..... 197
- extracellular on active transport processes (abst) ..... 409
- Fanconi syndrome (abst) ..... 296
- lactic ..... 752
- nephrectomy, effect on glutamine homeostasis (abst) ... 365
- newborns, treatment of ARF with CAVH. .... 908
- potassium depletion (abst) ..... 363
- potassium depletion during chronic metabolic (abst) ... 374
- respiratory inhibits cAMP HCO<sub>3</sub> secretion (abst) ..... 362
- respiratory, stimulates ammoniogenesis (abst) ..... 355
- substrate oxidation, ammoniagenic adaptation (abst) ... 356
- systemic, proton-ATPase in tubules (abst) ..... 368
- Acids
- heteropolyuronic, non-aluminum ..... S-120
- polyunsaturated ..... 279
- Acivicin effect on glutamine (abst) ..... 359
- Acquired renal cystic disease
- magnetic resonance imaging, ultrasound in (abst) ..... 196
- Actin-regulatory proteins
- are in apical cytoplasm of kidney collecting duct (abst) . 413
- Acute oliguric renal failure
- monoclonal antibodies in diagnosis of renal disease .... 142
- Acute postinfections GN (abst) ..... 1250
- Acute renal failure
- changing patterns and outcome of (abst) ..... 176
- chronic uremia, mouse model (abst) ..... 318
- cisplatin (abst) ..... 312
- endotoxemic (abst) ..... 306
- endotoxin-mediated, theophylline (abst) ..... 308
- HR effect on cisplatin-induced (abst) ..... 300
- insulin (abst) ..... 306
- ischemia, hypothyroidism protects against free radical. 1162
- ischemic, dipyridamole (abst) ..... 305
- laser Doppler velocimetry (abst) ..... 297
- mannitol in high risk patients (abst) ..... 298
- metabolic adaptations in renal disease ..... 80
- nephrotoxic in streptozotocin treated rats (abst) ..... 301
- nifedipine on carbohydrate metabolism (abst) ..... 1257
- norepinephrine-induced, vascular congestion ..... 306
- outcome prediction in (abst) ..... 184
- prostaglandins induced by captopril (abst) ..... 338
- proton magnetic resonance (abst) ..... 302
- reduced blood pressure (abst) ..... 256
- renal blood flow, prostaglandin in glycerol-induced
- (abst) ..... 342
- reversal due to urinary tract infection (abst) ..... 176
- ribonuclease II isozyme activity (abst) ..... 305
- TXA<sub>2</sub> in glycerol-induced (abst) ..... 42
- vascular aberrancies of (abst) ..... 299
- verapamil (abst) ..... 312
- Acute renal injury
- gasoline injection (abst) ..... 304
- Acute renal insufficiency
- reversible due to diuretic, Maxzide (abst) ..... 198
- Acute tubular necrosis
- autofluorescence (abst) ..... 289
- diabetes mellitus protects against (abst) ..... 308
- monoclonal antibodies in diagnosis ..... 142
- Adenine nucleotide degradation (abst) ..... 296
- Adenosine
- inhibits chloride secretion in shark rectal gland (abst) .. 337
- triphosphate levels ischemic insult (abst) ..... 310
- transport (abst) ..... 332
- Adenyl cyclase, PTH, H<sub>2</sub>O flow (abst) ..... 170
- Adenylate cyclase, vasopressin (abst) ..... 424
- Adrenal
- corticosteroids, transport(abst) ..... 407
- steroids, permeability (abst) ..... 417
- unilateral medullary hyperfunction (abst) ..... 245
- Adrenalectomized
- rabbit, K bicarbonate on Na-K-ATPase CCD (abst) .... 395
- Adrenalectomy, protein in uremic (abst) ..... 309
- Adrenoceptor
- alpha, assessment (abst) ..... 244

- posterior hypothalamic B-2 in SHR (abst) . . . . . 249
- Adult idiopathic nephrotic syndrome
- membranoproliferative glomerulonephritis in (abst) . . . . . 207
- Adult-onset nephrotic syndrome . . . . . 1250
- Age
- and PTH (abst) . . . . . 175
- donor influence on transplant(abst) . . . . . 942
- renal cortical brush border membrane enzyme activity (abst) . . . . . 360
- AIDS
- associated renal failure, national perspective (abst) . . . . . 201
- nephrotic syndrome (abst) . . . . . 288
- Albumin
- homeostasis, dietary protein . . . . . 572
- homeostasis in nephrotics . . . . . 572
- hyperoncotic, natriuresis (abst) . . . . . 392
- Albumin, bovine serum, binding (abst) . . . . . 265
- Albuminuria
- enalapril blocks (abst) . . . . . 320
- hyperlipimia (abst) . . . . . 193
- Aldosterone
- changes in short-circuit current and conductance (abst) . 408
- induced glycoproteins in toad (abst) . . . . . 351
- induces Cl transport in CCT (abst) . . . . . 1252
- in vivo . . . . . 208
- mineralcorticoid (abst) . . . . . 242
- 19-NOR potent (abst) . . . . . 253
- 19-OH, 19-NOR (abst) . . . . . 242
- Alkali
- nural regulation of excretion (abst) . . . . . 365
- therapy in CRF (abst) . . . . . 323
- Alkaline
- growth of proximal tubular cells occurs (abst) . . . . . 402
- Alkalinization
- canine renal proximal tubular cells, phorbol ester (abst) . 372
- Alkalosis
- chloride corrects without volume expansion (abst) . . . . 364
- chloride depletion, new dog model (abst) . . . . . 364
- volume expansion not correct acute chloride depletion (abst) . . . . . 365
- Allergy, food, and idiopathic NS (abst) . . . . . 776
- Allograft
- age of donor impact on survival (abst) . . . . . 942
- deposits of cyclosporine in (abst) . . . . . 612
- Alpha 2-adrenoceptors
- dopamine receptors in diuresis (abst) . . . . . 395
- Alpha-ketosiscaproate, uremic (abst) . . . . . 326
- Alport's syndrome
- epidermal basement membrane antigens (abst) . . . . . 279
- expression of Goodpasture antigen in . . . . . 202
- Alsosterone secretion, PTH (abst) . . . . . 168
- Aluminum
- addition on parathyroid tissue incubation medium . . . . 924
- and iron removal after DFO in CAPD, HD and HF (abst) . . . . . 171
- Australia, and bone disease in . . . . . S-65
- binding protein in bovine duodenal extracts (abst) . . . . 154
- bone biopsy and storage of (abst) . . . . . 173
- bone, longitudinal study . . . . . 218
- CaCO<sub>3</sub> on K, Ca, and Mg balance in ESRD (abst) . . . . . 219
- carbon, microencapsulated, used for removal (abst) . . . 226
- changes in bone histology after desferrioxamine treatment . . . . . S-108
- clearance of by hemodialysis, desferrioxamine . . . . . S-100
- desferoxamine treatment of anemia in dialysis (abst) . . . 210
- diagnosing bone disease . . . . . S-96
- dialysis encephalopathy . . . . . S-53
- effect on bone and cell localization . . . . . S-37
- effect on bone and cell localization . . . . . S-37
- elevated levels in CRF patients (abst) . . . . . 176
- enhanced gastrointestinal adsorption in uremic (abst) . . 1260
- erythropoiesis (abst) . . . . . 610
- experimental induced bone disease . . . . . S-32
- geochemistry . . . . . S-3
- hematopoiesis . . . . . S-45
- hemoperfusion in treatment of bone disease (abst) . . . . 214
- in genesis of osteodystrophy . . . . . 169
- interactions with cofactors, enzymes and proteins . . . . S-12
- intoxication of bone in renal failure . . . . . S-70
- metabolism . . . . . S-8
- Mg hydroxide, low Mg dialysate in CAPD (abst) . . . . . 232
- mineralization during matrix-induced bone development . . . . . 1038
- non, phosphate-binding compound . . . . . S-120
- parathyroid glands function despite exposure (abst) . . . . 170
- phosphate binding gels balance adsorption, toxicity . . . 1131
- plasma, toxicity . . . . . S-91
- PTH and vitamin D on intestinal and renal handling of (abst) . . . . . 173
- PTH and vitamin D3 affect accumulation (abst) . . . . . 213
- PTH not prevent osteomalacia . . . . . 168
- related bone disease, clinical & laboratory features (abst) . . . . . 199
- related osteodystrophy . . . . . 169
- removal during HD and CAPD, effect of DFO infusion (abst) . . . . . 190
- removal in home dialysis . . . . . 209
- serum and spinal fluid levels in HD uremics (abst) . . . . 211
- serum levels in dialysis patients (abst) . . . . . 165
- suppression of DNA synthesis by bone cells (abst) . . . . 157
- toxicity resembles aplastic bone disease (abst) . . . . . 164
- toxicity, experimental renal failure (abst) . . . . . 175
- Amiloride
- effect on bicarbonate (abst) . . . . . 375
- protects antiporter vs EEDQ (abst) . . . . . 405
- on transport (abst) . . . . . 163
- Na<sup>+</sup> channel (abst) . . . . . 1255
- Amino acid
- combined infusion of, and dopamine, renal hemodynamics . . . . . 870
- low protein, keto acid diet, risk and benefit . . . . . 995
- mercury in basolateral cell membrane (abst) . . . . . 416
- Na transport, lipid events, adaptive response to (abst) . . 413
- renal hemodynamics during infusion of, and dopamine . 870
- Aminoaciduria in rejection (abst) . . . . . 436
- Aminonucleoside
- nephrosis, heparin(abst) . . . . . 273
- of puromycin . . . . . 478
- Ammonia
- ammonium on Na/H antiporter, kinetic effects (abst) . . . 402
- concentration in inner medulla (abst) . . . . . 366
- genic adaptation to substrate oxidation, acidosis (abst) . 356
- inhibits tubule cell energy metabolism (abst) . . . . . 352
- K transport in turtle bladder (abst) . . . . . 377
- transport, transepithelial (abst) . . . . . 366
- tubular C3 deposit (abst) . . . . . 293
- Ammoniogenesis
- acetazolamide (abst) . . . . . 354
- acute respiratory acidosis stimulates (abst) . . . . . 355
- AT-125 on renal (abst) . . . . . 361

- gluconeogenesis, <sup>13</sup>C NMR, <sup>15</sup>N GC-MS (abst) . . . . . 357  
 plasma glutamine concentration (abst) . . . . . 351  
 regulation of glutamine metabolism in dog kidney . . . . . 68  
 renal cortical mitochondrial, PGE<sub>2</sub> (abst) . . . . . 355  
 valproate (abst) . . . . . 350  
 Ampflex connector (abst) . . . . . 237  
 Amphiuma  
   apical membrane conductance (abst) . . . . . 398  
 Amphiuma collecting tubule (abst) . . . . . 398  
 Amyloid  
   lambda 2 light chain (abst) . . . . . 288  
   type, diagnosis (abst) . . . . . 274  
   B2 microglobulin, carpal tunnel syndrome (abst) . . . . . 213  
 Amyloidosis  
   incidence in population of 250,000 (abst) . . . . . 777  
   in heroin abusers (abst) . . . . . 187  
 Anabolism in hemodialysis (abst) . . . . . 209  
 Analogs, adenosine on GFR (abst) . . . . . 358  
 Anaphylactic reactions, dialyzers (abst) . . . . . 212  
 Anaphylatoxin  
   cardiopulmonary effect of cuprophane-activated plasma . . 799  
   cobra venom factor(abst) . . . . . 269  
 Anemia  
   in hemodialysis (abst) . . . . . 214  
   chronic renal failure . . . . . 641  
 Anencephalic neonate donor  
   transplantation of cadaver kidneys from (abst) . . . . . 430  
 Aneurysm, glomerular (abst) . . . . . 286  
 ANFT, metabolic/excretory coupling(abst) . . . . . 360  
 Angiotensin  
   vasomotor response to reflex sympathetic activation  
     (abst) . . . . . 610  
 Angiotensin converting enzyme  
   clipped kidney in hypertensive rats during prolonged  
     (abst) . . . . . 246  
   experimental nephrotic syndrome (abst) . . . . . 302  
 Angiotensin II  
   aldosterone secretion, protein phosphorylation (abst) . . 329  
   binding sites in segments of rat nephron (abst) . . . . . 254  
   blood pressure, vascular reactivity (abst) . . . . . 383  
   BP control in normotensive members of hypertensive  
     families . . . . . 882  
   Ca kinetics . . . . . 424  
   calcium, cyclooxygenase modulate renal function (abst) . . 336  
   chronic salt loading, glomeruli (abst) . . . . . 385  
   hypertrophy vs. hyperplasia (abst) . . . . . 318  
   in nephrotoxic serum nephritis (abst) . . . . . 293  
   PGE<sub>2</sub> synthesis by pertussis toxin (abst) . . . . . 344  
   role for water intake (abst) . . . . . 1252  
 Antiotensin II  
   segmental vascular diameter response to (abst) . . . . . 381  
   vasopressin, cause membrane depolarization (abst) . . . 341  
   22Na<sup>+</sup> washout from VSMCs (abst) . . . . . 338  
 Anion exchange, band 3 (abst) . . . . . 376  
 Anionic sites  
   albumin excretion (abst) . . . . . 294  
   phosphate (abst) . . . . . 285  
 Anisotonic media regulation (abst) . . . . . 419  
 Anoxia, adenine nucleotides (abst) . . . . . 357  
 Anoxic cell death, Ca, nephron segment . . . . . 1172  
 Anoxic renal PT, acidosis (abst) . . . . . 299  
 Anti-diuretic hormone  
   cAMP, regulation of water permeability in bladder  
     (abst) . . . . . 417  
   fluorescent markers study membrane retrieval in (abst) . 416  
 Anti-glomerular basement membrane  
   antibody mediated disease, outcome (abst) . . . . . 200  
 Anti-inflammatory drug  
   sulinas effect during hemorrhage . . . . . 484  
 Anti-interleukin-2 receptor (abst) . . . . . 280  
 Anti-thymocyte globulin, CyA (abst) . . . . . 427  
 Antibiotic induced renal failure (abst) . . . . . 177  
 Antibiotic schedule for CAPD (abst) . . . . . 231  
 Antibodies  
   auto-anti-idiotypic in anti-GBM GN (abst) . . . . . 290  
   heparan sulfate proteoglycans of GBM (abst) . . . . . 283  
   monoclonal, to mononuclear cell markers . . . . . 708  
   MRL nephritogenic, share dominant ideotype (abst) . . . 285  
   to laminin in preeclampsia . . . . . 1050  
   viral glycoprotein, endocytosis (abst) . . . . . 420  
   immune complex (abst) . . . . . 271  
   monoclonal Enkephalin degrading enzyme (abst) . . . . . 271  
   monoclonal in diagnosis . . . . . 142  
 Antibody  
   anti-GBM in auto-immune nephritis . . . . . 266  
   antigen, in heymann nephritis (abst) . . . . . 608  
   antigliadin in IgA glomerulonephritis (abst) . . . . . 776  
   characterization of monoclonal, Tamm-Horsfall protein . . 971  
   monoclonal anti-rat-thymocyte, glomerulonephritis  
     (abst) . . . . . 945  
   reaginic ETO response (abst) . . . . . 266  
   to acidic protein MAUP in urine (abst) . . . . . 264  
   urinary calcium oxalate crystal growth inhibitor . . . . . 829  
 Antibody binding  
   tubular C3 deposition by ammonia (abst) . . . . . 293  
 Antidiuresis  
   increased urinary excretion of PGE<sub>2</sub> . . . . . 1110  
 Antidiuretic hormone  
   mechanism of in natriuresis (abst) . . . . . 422  
   nucleotide regulatory protein mediates (abst) . . . . . 423  
   type B syndrome of inappropriate (abst) . . . . . 421  
 Antigen  
   antibody, glomerular capillary wall charge interactions . 649  
   exogenous cationized, Heymann Nephritis (abst) . . . . . 264  
   immunocytochemical localization of renin and  
     kallikrein . . . . . 965  
   nucleic acid, membranous lupus autoantibodies (abst) . . 288  
   of antiglomerular basement membrane antibody (abst) . 1248  
 Antigen-antibody systems  
   Heymann Nephritis (abst) . . . . . 263  
   70KD, HN (abst) . . . . . 291  
 Antigens  
   HLA-DR, DP, DQ, on human tissue (abst) . . . . . 1261  
   immunodissection and culture of CCT (abst) . . . . . 424  
   microheterogeneity, nephritis, 2D-SDS immunoblotting  
     (abst) . . . . . 1249  
   MHC minimal change glomerulonephritis, focal sclero-  
     sis (abst) . . . . . 286  
   multiple, MRL antibody (abst) . . . . . 285  
 Antihypertensive  
   drug, guanabenz . . . . . 1203  
   hepatic dysfunction in transplant (abst) . . . . . 438  
   treatment, effects in one-clip, two kidney hypertension . . 1011  
   therapy, decrease of NAG after (abst) . . . . . 258  
 Antiport  
   Na activates Na-H activity at internal locus (abst) . . . . 396  
   Na-H activity in LLC-PK1-CL4 cells (abst) . . . . . 403  
 Antiporter  
   kinetics of Na-H, pH in MDCK cells (abst) . . . . . 376  
   Na<sup>+</sup>/H<sup>+</sup>, amiloride protects vs inactivation (abst) . . . . 405



- Na<sup>+</sup>/H<sup>+</sup>, CL<sup>-</sup>/HCO<sub>3</sub><sup>-</sup>(OH<sup>-</sup>) transport NaCl (abst) . . . . 390  
 Na/H and PTH (abst) . . . . . 372  
 with exchanger, BBM (abst) . . . . . 367  
 APD, hyperparathyroidism (abst) . . . . . 1262  
 Apical membrane vesicles  
   LLC-PK1, new type of exchange system of Na<sup>+</sup>/H<sup>+</sup>  
   (abst) . . . . . 373  
 Aplastic bone disease, dialysis . . . . . S-74  
 Arachidonate acid epoxigenase (abst) . . . . . 356  
 Arachidonic acid  
   metabolites, prostaglandins in the kidney . . . . . 108  
 Arginine infusion  
   on renal plasma flow and GFR in humans (abst) . . . . . 190  
 Arginine vasopressin  
   action (abst) . . . . . 328  
   action cellular calcium uptake modulates in CCT (abst) . 415  
   analysis . . . . . 178  
   mechanism in MAL (abst) . . . . . 418  
   pertussis toxin, adenylate cyclase activity (abst) . . . . 426  
   modulation of hormonal action by . . . . . 863  
   receptor characteristics of human platelet (abst) . . . . 412  
 Arterial  
   dopamine-2 receptor in canine kidney (abst) . . . . . 385  
 Arterial line, blood in HD (abst) . . . . . 943  
 Arteries, renal  
   endothelium-dependent relaxation (abst) . . . . . 251  
 Arterioles  
   isolated renal afferent, PGE<sub>2</sub> (abst) . . . . . 385  
   glomerular, AII (abst) . . . . . 333  
 Arteriovenous shunting (abst) . . . . . 195  
 Arthritis  
   rheumatoid, CyA, Aza side effects in treatment of . . . 1180  
 Aspirin, GFR (abst) . . . . . 323  
 Assay  
   D valine medium (abst) . . . . . 353  
   new chromogenic endotoxin (abst) . . . . . 207  
   PTH in CAPD (abst) . . . . . 239  
 AT-125, ammoniogenesis (abst) . . . . . 361  
 Atenolol in hypertensives (abst) . . . . . 205  
 Atomic absorption spectroscopy  
   electrothermal determination of aluminum . . . . . S-28  
 Atomic emission spectrometry, aluminum . . . . . S-24  
 ATPase  
   acetate intolerance during HD (abst) . . . . . 223  
   activity in proximal tubule brush border membrane  
   (abst) . . . . . 368  
   clathrin-coated vesicle proton translocating (abst) . . . 378  
   depletion . . . . . 302  
   distribution and function along the nephron . . . . . 21  
   luminal active transport processes in cortical cells  
   (abst) . . . . . 611  
   mechanism, produced by exogenous nucleotides (abst) . 356  
   monoclonal antibody to bovine medulla H<sup>+</sup> . . . . . 369  
   mutant clathrin-coated vesicle proton translocating  
   (abst) . . . . . 377  
   Na-K, in streptozotocin-induced diabetes mellitus  
   (abst) . . . . . 410  
   recovery, postischemic (abst) . . . . . 299, 315  
   sodium pump in salt gland, gut tube of brine shrimp  
   (abst) . . . . . 394  
   sodium transport, oxygen consumption and . . . . . 3  
   to sodium transport (abst) . . . . . 359  
 Atrial extracts, properties, rat (abst) . . . . . 248  
 Atrial natriuretic factor  
   acute hormonal and hemodynamic effects of in man  
   (abst) . . . . . 1253  
   aorto-caval fistula (abst) . . . . . 389  
   causes glomerular hyperfiltration, cAMP, TGF (abst) . . 384  
   changes in dietary protein (abst) . . . . . 384  
   chronic sodium homeostasis . . . . . 1004  
   furosemide induced natriuresis (abst) . . . . . 398  
   in salt-sensitive DAHL rats (abst) . . . . . 334  
   in vascular smooth muscle cells (abst) . . . . . 258  
   increase excretion, GFR (abst) . . . . . 332  
   induce a natriuresis, GFR (abst) . . . . . 402  
   intrarenal effects of (abst) . . . . . 408  
   medullary solute gradients (abst) . . . . . 414  
   ouabain factor, high Na diet (abst) . . . . . 404  
   plasma and urine levels following ANF infusion (abst) . 409  
   plasma, hypervolemia (abst) . . . . . 395  
   relationship between, and renal kallikrein (abst) . . . . 1254  
   respiration (abst) . . . . . 340  
 Atrial natriuretic peptide  
   acute hemodynamic effect of (abst) . . . . . 383  
   angiotensin II and hyperoncotic albumin (abst) . . . . 340  
   artificial heart transplant (abst) . . . . . 192  
   atrial resection limits in sodium excretion (abst) . . . . 407  
   blood levels, cardiovascular, endocrine, excretory  
   (abst) . . . . . 348  
   diabetes insipidus, natriuretic effect (abst) . . . . . 390  
   dopamine (abst) . . . . . 336  
   during mineralocorticoid escape (abst) . . . . . 329  
   effect of on kidney and juxtamedullary nephron (abst) . . 405  
   effects of on kidney function in man (abst) . . . . . 388  
   hydraulic pressures, natriuresis (abst) . . . . . 382  
   in plasma of children with ESRD and volume expan-  
   sion (abst) . . . . . 1254  
   increase plasma insulin (abst) . . . . . 348  
   inhibitory effect of on cAMP in glomeruli (abst) . . . . 425  
   levels during saline volume expansion (abst) . . . . . 406  
   release in calves with artificial heart (abst) . . . . . 389  
   sodium intake (abst) . . . . . 384  
   synthetic, control of GFR (abst) . . . . . 393  
   mechanism of natriuretic (abst) . . . . . 383  
 Atriopeptin III  
   atrial extract in rat (abst) . . . . . 401  
   influence on rabbit aortic smooth muscle, cGMP (abst) . . 1254  
   in primate (abst) . . . . . 392  
   kinetics (abst) . . . . . 340  
 Atriopeptins, glomerular effects (abst) . . . . . 379  
 Australia, aluminum, bone disease in . . . . . S-65  
 Autoantibodies  
   membranous lupus crossreact with nucleic acid antigen  
   (abst) . . . . . 288  
   to tubular antigens, gold nephropathy . . . . . 539  
   lupus SLE (abst) . . . . . 283  
 Autoantibody, Goodpasture Syndrome(abst) . . . . . 287  
 Autofluorescence  
   diagnosis of acute tubular necrosis (abst) . . . . . 289  
 Autoimmunity  
   DNA (abst) . . . . . 268  
   murine, Ia (abst) . . . . . 289  
 Autosomal dominant polycystic  
   kidney disease, cyst infection in (abst) . . . . . 203  
   kidney disease . . . . . 315  
 AVP  
   increased urinary excretion of PGE<sub>2</sub> during  
   antidiuresis . . . . . 1110

- Axotemia, trends after HD (abst) ..... 224  
 Azathioprine  
   CyA, rheumatoid arthritis ..... 1180  
   in renal transplantation (abst) ..... 435  
   measure 6TU (abst) ..... 437  
 Azlocillin's kinetics (abst) ..... 208  
 Azotemia  
   rats, B6 deficiency (abst) ..... 228  
   trends after HD (abst) ..... 224  
 $\alpha$ 2-adrenoceptor, PGE2, cAMP levels ..... 703  
  
**B** cell hyperactivity in IgA ..... 718  
 B cell in aTBM (abst) ..... 270  
 Bacterial microcolonies  
   in peritonitis associated with CAPD (abst) ..... 230  
 Bartter syndrome  
   diluting segment function abnormal (abst) ..... 416  
   enalapril (abst) ..... 190  
   tests of renal diluting ability determine cause (abst) ..... 190  
 Basement membrane  
   anti-glomerular, antibody mediated disease (abst) ..... 200  
 Basolateral amiloride  
   acidification (abst) ..... 371  
 Basolateral membrane vesicles  
   cotransport of NaHCO<sub>3</sub> (abst) ..... 362  
   Na-HCO<sub>3</sub> cotransport (abst) ..... 367  
   membranes, IGF I (abst) ..... 354  
 Bence Jones Protein, toxicity (abst) ..... 309  
 Berger's Disease (abst) ..... 191  
 Beta blockade, ISA alters (abst) ..... 257  
 Beta 2 microglobulin, ADPKD (abst) ..... 315  
 Bicarbonate  
   amiloride effect on permeability (abst) ..... 375  
   buffered, solution for parenteral use (abst) ..... 369  
   diuresis, PCO<sub>2</sub> (abst) ..... 373  
   PK of at high, low concentrations (abst) ..... 377  
   reabsorption across distal tubule ..... 365  
   regulation of glutamine metabolism in dog kidney ..... 68  
   renal acid-base metabolism after ischemia ..... 989  
 binding sites, AII (abst) ..... 254  
 Binding, glomerular, BSA (abst) ..... 265  
 Biophosphonate, APD, parathyroid (abst) ..... 941  
 Biopsy  
   adolescents with renal disease (abst) ..... 207  
   fine needle aspiration, transplanted kidney (abst) ..... 430  
   renal allograft, value in cyclosporine era (abst) ..... 438  
   renal and fine-needle aspiration in transplantation  
     (abst) ..... 612  
   renal in elderly (abst) ..... 204  
   65 teenagers with primary nephrotic syndrome (abst) .. 284  
 Blocking agents  
   Ca++ activated K+ channels in MTAL (abst) ..... 396  
 Blood  
   flow measurement, noninvasive Doppler method (abst) . 379  
   flow, temporal and spatial analysis (abst) ..... 380  
   red cells, sodium transport in, dialyzed uremics ..... 1197  
   transfusion, HLA-A, B compatible in transplantation  
     (abst) ..... 612  
 Blood pressure  
   after radical operation in secondary hypertension (abst) . 247  
   altered by maternal dietary calcium in dogs (abst) .... 254  
   captopril on renal hemodynamics (abst) ..... 382  
   cardiovascular response to hemofiltration ..... 901  
   Ca<sup>2+</sup> in hypertensive (abst) ..... 262  
   determinants of in renal transplantation (abst) ..... 436  
   effects of Ca are prevented by magnesium (abst) ..... 263  
   elevated and rapid loss of renal function in NIDDM  
     (abst) ..... 182  
   glomerular injury to preglomerular resistance, hyper-  
     tension ..... 849  
   house officers during on call (abst) ..... 253  
   lead exposure, calcium intake (abst) ..... 198  
   NaCl effect in rat (abst) ..... 255  
   normotensive members of hypertensive families ..... 882  
   pregnancy, renin angiotensin aldosterone system (abst) . 777  
   reduced, acute renal dysfunction in hypertension (abst) .. 256  
   renal function in kidney donors ..... 1072  
   renal function preservation due to reduction (abst) .... 320  
  
**Bone**  
   accumulation of aluminum, osteomalacia ..... S-17  
   AL intoxicated rats, increased 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors  
     (abst) ..... 165  
   aluminum metabolism ..... S-8  
   Aluminum, longitudinal study (abst) ..... 218  
   aluminum, PTH and vitamin D<sub>3</sub> affect (abst) ..... 213  
   aluminum, transferrin-dependent, suppression of DNA  
     (abst) ..... 157  
   aplastic disease, AL toxicity (abst) ..... 164  
   biopsy and Al storage (abst) ..... 173  
   biopsy, aluminum and bone disease in Australia ..... S-65  
   changes in histology after desferrioxamine treatment . S-108  
   children, renal disease in dialyzed (abst) ..... 236  
   density in hypertension ..... 205  
   development, Al on mineralization during  
     matrix-induced ..... 1038  
   diagnosis of aluminum disease ..... S-96  
   disease, aluminum-related ..... S-80  
   disease, experimental aluminum-induced ..... S-32  
   disease, PTH in aluminum ..... S-87  
   effects of dietary calcium and sodium on (abst) ..... 173  
   formation, aluminum influence ..... S-32  
   formation, calcium efflux (abst) ..... 156  
   fracturing disease, dialysis encephalopathy ..... S-53  
   increased receptors in AL intoxicated rats (abst) ..... 165  
   ion microprobe determination of surface elements  
     (abst) ..... 164  
   marrow transplant, cytomegalovirus glomerulopathy . 725  
   Newcastle disease, aluminum-induced osteodystrophy . S-58  
   protective effect of verapamil on resorption (abst) ..... 156  
   scan, 99mTc-methylene diphosphonate in osteodystro-  
     phy ..... 1058  
   unresponsiveness of, to PTH in Al-related osteodystro-  
     phy ..... S-49  
   1,25(OH)<sub>2</sub>D<sub>3</sub> and PTH maintain activity of cells (abst) . 164  
 Bone marrow transplantation  
   renal vasodilation and hyperfiltration (abst) ..... 206  
 Bovine hemoglobin, renal function (abst) ..... 301  
 Bowel infarction in dialysis (abst) ..... 212  
 Bowman's capsule  
   crescents in CGn (abst) ..... 266  
 Bradykinin  
   cortical interstitial cells (abst) ..... 347  
   kallidin metylsbradykinin ..... 121  
   kallikrein ..... 953  
   lipid peroxidation (abst) ..... 333  
   quin 2 fluorescence in papillary collecting tubule (abst) . 344  
   radioimmunoassay using monoclonal antibodies (abst) . 342  
 Brain buffering, K depletion (abst) ..... 362  
 Brain infarcts, K diet reduces (abst) ..... 250  
 Bright's disease ..... 779

- Bronchopneumonia, IgA ..... 557
- Brush border membrane
- age related changes in water, solute permeability (abst) .. 414
  - basolateral, fluidity differences in (abst) ..... 403
  - carbonic anhydrase in S3 segment (abst)..... 370
  - cortical, effects of aging on (abst) ..... 360
  - heterogeneity of fractions isolated by centrifugation (abst) ..... 361
  - Na<sup>+</sup>/H<sup>+</sup> antiporter with exchanger (abst) ..... 367
  - permeabilities and fluidity of in cortex (abst) ..... 412
  - phorbol esters stimulate Na<sup>+</sup>/H<sup>+</sup> (abst)..... 408
  - phospholipids induced by mercuric chloride..... 496
  - proteins, phosphatidylcholine transfer (abst)..... 174
  - transport of H<sup>+</sup>/OH<sup>-</sup> (abst) ..... 378
  - vesicles, cimetidine uptake (abst) ..... 420
- Brush border membrane vesicle
- Cl/OH exchange coupled by electrical potential (abst) .. 370
  - electrolyte gradients in, 3 techniques (abst) ..... 402
  - fraction from human renal cortex (abst) ..... 352
  - kinetic studies of Na<sup>+</sup>-H<sup>+</sup> (abst) ..... 370
  - phosphate uptake (abst) ..... 155
  - presteady state kinetics of Na<sup>+</sup>-H<sup>+</sup> exchange (abst) ... 374
  - proximal convoluted tubules (abst) ..... 352
- c-sis mRNA in renal tissue (abst) ..... 272
- Calcification, vascular in HD (abst) ..... 213
- Calcitonin metabolism (abst) ..... 359
- Calcitriol
- effects of diuretics (abst) ..... 160
  - hyperparathyroidism (abst) ..... 199
  - relationship between urinary calcium and calcium intake ..... 578
  - vitamin D3 (abst) ..... 1255
- Calcium
- absorption in spontaneously hypertensive rat (abst) ... 159
  - activated K<sup>+</sup> channels in MTAL (abst) ..... 396
  - alters blood pressure in dogs (abst)..... 254
  - and cyclic AMP messenger function ..... 90
  - antagonists in hypertension (abst) ..... 241
  - antagonists on vasoconstrictor prostacyclin (abst) ..... 260
  - arginine vasopressin action in CCT (abst)..... 415
  - augments glomerular capillary hypertension, injury (abst) ..... 244
  - a2 and b2 adrenoceptors and free intracellular (abst) .. 1258
  - carbonate responsible for acid-induced release (abst) ... 156
  - carbonate, aluminum free agent for control in uremia. S-114
  - Ca2<sup>+</sup> efflux rate constant in isolated SHR enterocytes (abst) ..... 252
  - Ca2<sup>+</sup>, body composition changes in SHR (abst) ..... 248
  - channel blockade, antihypertensive efficacy of (abst) ... 257
  - channel blocker following ischemia (abst)..... 433
  - compensatory renal growth by Ca PTH, 1,25(OH)2D3. 1124
  - cortical mitochondria transport (abst) ..... 315
  - creatinine, renal net acid excretion ..... 743
  - cyclooxygenase products modulate renal function (abst) ..... 336
  - cytosolic Ca2<sup>+</sup>, fura 2, quin 2 measurement (abst) .... 399
  - dietary effect in hypertension. .... 166
  - dietary supplementation in hypertension (abst)..... 241
  - dietary, genetic variability in response to (abst) ..... 247
  - effect of Al on parathyroid tissue incubation medium .. 924
  - effect on BP and Na, K-ATPase in SHR (abst) ..... 262
  - efflux (abst)..... 156
  - gentamicin induces abnormalities (abst) ..... 298
  - hypercalcemia, role of loop segment in urinary concen-
  - trating ..... 977
  - hyperpolarization of proximal tubule cells (abst) ..... 393
  - impaired vasopressin, cAMP formation by increased (abst) ..... 425
  - increased intestinal transport in hypertensive rat (abst) . 244
  - influx and H2O distribution in aorta, hypertensive (abst) ..... 243
  - inositol triphosphate-sensitive pool (abst) ..... 157
  - inositol 1,4,5-triphosphate releases ..... 695
  - insulin, reactivity in diabetic (abst) ..... 315
  - intracellular free, circulating plasma factor (abst)..... 250
  - ionized modulates renal function (abst)..... 381
  - kinetics, angiotensin II (abst)..... 424
  - lead exposure and blood pressure (abst) ..... 198
  - measurement by FURA-2 (abst) ..... 335
  - mobilization of vasopressin receptors (abst) ..... 415
  - mobilizing hormones on brush border and sytoskeleton (abst) ..... 160
  - modulation by verapamil of hormonal action ..... 863
  - mucosal removal on a leaky epithelium (abst) ..... 422
  - Na<sup>+</sup>, pressor response to norepinephrine (abst)..... 261
  - nephron segment and, determinants of anoxic cell death ..... 1172
  - net acid excretion determines fasting urinary calcium .. 743
  - overload in ischemic renal injury (abst)..... 300
  - oxygen free radical injury (abst) ..... 305
  - phosphate precipitation, aluminum ..... S-20
  - phospholipid dependent protein kinase (abst) ..... 355
  - PTH activated, conductive pathway in brush border (abst) ..... 166
  - PTH stimulates cellular absorption of (abst)..... 159
  - renal channel abnormality in hypertensive rat (abst) ... 259
  - sequential changes, PTH secretion and UcAMP excretion (abst) ..... 172
  - sequestration in LLC-PK1 cells (abst)..... 302
  - stone former, hydrochlorothiazide (abst)..... 775
  - stone formers, soft vs. hard water (abst)..... 778
  - stress, hypertension in SHR (abst) ..... 247
  - toxicity to renal medulla (abst) ..... 298
  - urinary and intake relationship during calcitriol therapy .. 578
  - urinary, oxalate crystal growth inhibitor ..... 829
  - urine excretion post renal mass reduction (abst)..... 321
- Calcium oxalate, uremic serum (abst) ..... 315
- Calelectrin in renal tissue (abst)..... 291
- cAMP
- acidosis inhibits HCO3 secretion in turtle (abst)..... 362
  - mediates PTH stimulation of 25-OH-vitamin D3 activity (abst) ..... 162
  - process for K groups in glomerular polyanion complex (abst) ..... 285
  - protein kinase and Na<sup>+</sup>/H<sup>+</sup> exchange (abst) ..... 378
  - regulation of levels by PGE2 and a2 adrenoceptors ... 703
  - system, AII, AVP, Bradykinin, Meclofenamate on PG and (abst) ..... 341
  - system, beta-adrenoceptors coupled to (abst) ..... 335
- Campylobacter pericarditis (abst)..... 228
- Cancer
- renal, inhibitory effect of 1a,25-dihydroxyvitamin D3. ... 834
- Cancer chemotherapy
- acute hyponatremia during forced diuresis (abst) ..... 191
- CAPD
- air under diaphragm significance (abst) ..... 233
  - an initial dialysis modality? (abst) ..... 235
  - antibiotic delivery, new (abst) ..... 231
  - biofilm producing peritonitis (abst) ..... 230



- CCPD, children, peritoneal membrane function (abst) . . . 238  
 high dialysate Ca, i.p. 1,25(OH)2D3 on PTH (abst) . . . 231  
 intraperitoneal contrast, C-T scan (abst) . . . 237  
 levels of catecholamines, plasma renin activity, PA  
 (abst) . . . 238  
 limulus lysate assay diagnose GNP (abst) . . . 239  
 malignancies in (abst) . . . 231  
 peritoneal transport assessment . . . 941  
 peritonitis by eicosanoids (abst) . . . 237  
 peritonitis, leukocyte esterase testing (abst) . . . 234  
 prostaglandin-mediated loss of proteins during peritonitis . . . 584  
 protein binding of cefamandole during (abst) . . . 239  
 renal osteodystrophy in (abst) . . . 237  
 treatment of peritonitis with vancomycin (abst) . . . 229  
 Trimethoprim-sulfamethoxazole pharmacokinetics  
 (abst) . . . 236  
 zinc metabolism (abst) . . . 234
- Capillary leak syndrome  
 systemic edema (abst) . . . 181
- Captopril  
 altered renin-angiotensin-aldosterone system (abst) . . . 257  
 BP without kinins (abst) . . . 1259  
 enhanced renal flow study, hypertension (abst) . . . 254  
 geriatric hypertensives (abst) . . . 249  
 hemodynamics and BP during pregnancy (abst) . . . 382  
 improves lupus nephritis in mice (abst) . . . 277  
 peritoneal transport (abst) . . . 233  
 prostaglandins during ARF (abst) . . . 338  
 uropathy (abst) . . . 331  
 vasopressin induced bladder water flow, PGE2 (abst) . . . 420
- Carbon dioxide  
 stimulates growth of proximal tubule cells (abst) . . . 363
- Carbonic anhydrase  
 inhibitor (abst) . . . 379  
 pH in tubule (abst) . . . 364  
 S3 tubule (abst) . . . 370
- Cardiac  
 blood membrane contact during hemodialysis (abst) . . . 1260  
 modulation of plasma, platelet vasopressin by function . . . 1188  
 output, renal blood flow, leukotriene (abst) . . . 379  
 rehabilitation after renal transplantation (abst) . . . 1263
- Cardiopulmonary, cuprophane plasma, pig . . . 799
- Cardiovascular  
 atrial natriuretic peptide release, artificial heart (abst) . . . 389  
 BP control in normotensive members of hypertensive  
 families . . . 882  
 effects of atrial natriuretic peptide (abst) . . . 348  
 response to hemofiltration . . . 901
- Carpal tunnel syndrome amyloid (abst) . . . 213
- Catecholamines in IRF (abst) . . . 310
- Cathepsin activity, protein (abst) . . . 293
- Catheter  
 covering membrane probably focus of infection (abst) . . . 232  
 jugular vein cannulation with two silastic (abst) . . . 778  
 need for swan neck tunnel peritoneal dialysis (abst) . . . 238  
 peritoneal dialysis, urokinase restores (abst) . . . 235  
 silastic tenckhoff in CAPD (abst) . . . 239  
 subclavian HD, complications of (abst) . . . 226
- Cation  
 Na,K-ATPase in kidney . . . 13  
 organic, competition with transport of TEA, morphine  
 (abst) . . . 423  
 regulation of renal acid secretion in distal nephron seg-  
 ment . . . 1099
- Cefamandole during CAPD (abst) . . . 239
- Cell  
 anoxic death, nephron segment and Ca as determinants  
 of . . . 1172  
 electrical properties of collecting duct (abst) . . . 1252  
 human glomerulus, lipoprotein receptor activity (abst) . . . 1248  
 hypoxic injury in proximal tubule . . . 1021  
 MDCK, regulation of potassium conductance in (abst) . . . 1251  
 physiology of glandular kallikrein . . . 953  
 T and B markers, mononuclear cell subsets . . . 1043  
 T, defect, impaired immune responses in CRF . . . 1251
- Cephalosporin transport (abst) . . . 1256
- Cerebrovascular disease, stenosis (abst) . . . 262
- cGMP  
 atrial natriuretic factor causes, hyperfiltration (abst) . . . 384  
 atriopeptin III on rabbit aortic smooth muscle (abst) . . . 1254  
 ANF . . . 258  
 atriopeptin III (abst) . . . 1254
- Channel, Na  
 solubilization of epithelial (abst) . . . 400
- Channels, K and Cl<sup>+</sup> in membrane (abst) . . . 399
- Chelation kinetics during DFO (abst) . . . 226
- Children  
 hemolytic-uremic syndrome in (abst) . . . 179, 204  
 immune complexes and immunoglobulins (abst) . . . 269
- Chlorhexidine, SEP (abst) . . . 234
- Chloride  
 acute volume expansion on tubuloglomerular feedback  
 (abst) . . . 388  
 channel in bovine kidney medullary vesicles (abst) . . . 398  
 concentrations, hospital-associated hyponatremia . . . 1237  
 corrects alkalosis without volume expansion (abst) . . . 364  
 deficiency in neonates (abst) . . . 187  
 depletion in alkalosis in dog (abst) . . . 364  
 dietary determines NaCl-sensitive hypertension (abst) . . . 250  
 KCl loading increases absorption (abst) . . . 411  
 raw foods and sodium content . . . 262  
 secretion in A6 epithelia (abst) . . . 411  
 secretion in shark (abst) . . . 37  
 urine samples (abst) . . . 186  
 volume expansion not correct alkalosis (abst) . . . 365
- Chlorpromazine, Heymann Nephritis (abst) . . . 268
- Cholera toxin  
 increases water permeability (abst) . . . 417
- Cholesterol metabolism in ESRD (abst) . . . 224
- Chromosome 16 and PKD (abst) . . . 181
- Chronic desferrioxamine therapy  
 bone aluminum intoxication . . . S-70
- Chronic liver disease  
 hypercalcemia, a new complication of (abst) . . . 188
- Chronic obstructive bronchiolitis, IgA 557
- Chronic peritoneal dialysis  
 associated with progressive thrombocytosis (abst) . . . 240
- Chronic renal disease  
 Bright's . . . 779  
 clonidine abates (abst) . . . 327  
 glomerulonephritis types, prevalence in dogs . . . 1144
- Chronic renal failure  
 acute hyperaluminemic encephalopathy (abst) . . . 178  
 alkali therapy suppresses muscle proteolysis (abst) . . . 323  
 aluminum effect on parathyroid hormone secretion . . . S-41  
 Australian aluminum and renal bone disease . . . S-65  
 BP and renal function preservation (abst) . . . 320  
 changes in bone histology after desferrioxamine treat-  
 ment . . . S-108

- children, different dialysis modalities on growth (abst) . . . 233  
 elevated free copper (abst) . . . . . 326  
 energy intake on nitrogen metabolism in nondialyzed . . 734  
 evolution (abst) . . . . . 317  
 heart, secondary hyperparathyroidism (abst) . . . . . 317  
 hematopoietic inhibitors . . . . . 641  
 hyperlipidemia (abst) . . . . . 326  
 immunodeficiency in early stage of (abst) . . . . . 1257  
 impaired immune responses, T cell defect . . . . . 1209  
 increased oxalate (abst) . . . . . 321  
 non-aluminum phosphate binding compound . . . . . S-120  
 phosphate depletion arrests progression . . . . . 658  
 prolactin levels with MD therapy (abst) . . . . . 322  
 PTH secretion in aluminum bone disease . . . . . S-87  
 reduced circulating 1,25(OH)2D3 in development of  
 (abst) . . . . . 155  
 response to dopamine blockade (abst) . . . . . 194  
 role of plasma aluminum in toxicity . . . . . S-91  
 verapamil (abst) . . . . . 319  
 Chronic renal injury, salt (abst) . . . . . 244  
 Chronic renal insufficiency  
   furosemide in, (abst) . . . . . 180  
   protein restriction (abst) . . . . . 318  
 Chronic serum sickness, GLN . . . . . 841  
 Cimetidine, BBMV (abst) . . . . . 420  
 Circadian rhythm, nephrotics (abst) . . . . . 942  
 Circulation, remnant nephron (abst) . . . . . 384  
 Cirrhosis  
   interstitial fluid in (abst) . . . . . 381  
   liver IgA nephropathy in patients with (abst) . . . . . 1258  
   prostaglandins in rats (abst) . . . . . 343  
   prognostic factors (abst) . . . . . 184  
   renal dysfunction . . . . . 598  
   unable to increase GFR after protein loading (abst) . . . 185  
 Cisplatin, ARF (abst) . . . . . 312  
   PST, cations (abst) . . . . . 306  
   WR-2721 against (abst) . . . . . 311  
 Cl/OH exchange, BBV (abst) . . . . . 370  
 Clearance  
   human antibody/DNA immune complexes, circulation  
   (abst) . . . . . 277  
 Clofibrate acid, nephrectomy (abst) . . . . . 324  
 Clonidine  
   chronic renal disease (abst) . . . . . 327  
   transdermal (abst) . . . . . 251  
 CMV antibody, IgA, transplant (abst) . . . . . 277  
 CMV-prophylaxis after transplant (abst) . . . . . 1262  
 Cobra venom factor anaphylatoxins (abst) . . . . . 269  
 Collagen binding reduced, Fn-N (abst) . . . . . 267  
 Collecting duct  
   apical membrane, cation conductance channels (abst) . . 393  
   cells, apical sodium uptake by papillary (abst) . . . . . 399  
   electrical (abst) . . . . . 1252  
   H-pump (abst) . . . . . 369  
   kidney, actin-regulatory proteins locate in (abst) . . . . 413  
   medullary, function during medullary vasodilation  
   (abst) . . . . . 394  
   mesonephric, H<sup>+</sup> secretion (abst) . . . . . 376  
   outer medullary, electrophysiologic identification (abst) . . 400  
 Colloid volume  
   expansion on glomerular barrier . . . . . 916  
 Compensatory renal growth, modulation . . . . . 1124  
 Compensatory renal hypertrophy  
   ornithine decarboxylase activity and polyamines (abst) . 357  
 Complement  
   alternate pathway by B cell in MPGN (abst) . . . . . 278  
   antibody-induced mesangial cell damage (abst) . . . . . 296  
   C5 in glomerulonephritis (abst) . . . . . 274  
   erythrocytes inhibit (abst) . . . . . 273  
   induced cell injury (abst) . . . . . 272  
 Concentric ventricular hypertrophy (abst) . . . . . 217  
 Congestive heart failure, CAVH (abst) . . . . . 226  
 Connecting tubules  
   beta adrenoceptors coupled to cAMP system (abst) . . . . 335  
 Connector, amplex (abst) . . . . . 237  
 Conn's syndrome  
   hypertension with increased 18-OH-B (abst) . . . . . 1259  
 Contamination of aluminum  
   control . . . . . S-24  
   electrothermal determination . . . . . S-28  
 Continuous arterio-venous hemofiltration  
   in newborns with ARF . . . . . 908  
   hemodynamic consequences of in intractable fluid  
   (abst) . . . . . 218  
   routine filter life of (abst) . . . . . 219  
 Contraceptive, oral, HUS (abst) . . . . . 777  
 Converting enzyme inhibition  
   effects of antihypertensive treatment . . . . . 1011  
   renal hemodynamic stability in hypertension (abst) . . . . 255  
 Copper, free, in CRF (abst) . . . . . 326  
 Coronary angiography, RCA (abst) . . . . . 309  
 Coronary revascularization (abst) . . . . . 427  
 Cortex  
   inner, outer, brush border membrane vesicle fluidity  
   (abst) . . . . . 412  
 Cortical cells  
   extracellular acidosis on active transport (abst) . . . . . 409  
 Cortical collecting duct  
   lumen, radial pH gradient in (abst) . . . . . 377  
   Na-dependent aldosterone stimulation of (abst) . . . . . 397  
 Cortical collecting tubule  
   chloride transport pathways (abst) . . . . . 409  
 Cortical interstitial cells  
   sensitivity of hydronephrotic kidney to bradykinin  
   (abst) . . . . . 347  
 Cortical mitochondria, CyA (abst) . . . . . 311  
 Creatinine  
   chronic renal failure, evolution (abst) . . . . . 317  
   clearance, glomerular filtration surface in diabetes . . . . 889  
   clearance in NIDDM (abst) . . . . . 179  
   prognosis and treatment of membranous nephropathy . . 927  
   reciprocal of serum, reliable to assess change (abst) . . . 325  
 Crescentic glomerulonephritis (abst) . . . . . 189  
 Crescentic proliferative GN (abst) . . . . . 267  
 Crescents  
   cellular, CGn-Bowman's (abst) . . . . . 266  
   glomerular, epithelial origin (abst) . . . . . 278  
   identification in crescentic glomerulopathies (abst) . . . . 775  
 Cryoglobulinemia, Fc receptor (abst) . . . . . 608  
 Cryoprotective dimethyl sulfoxide (abst) . . . . . 431  
 Crystal  
   bone, effect of aluminum on . . . . . S-37  
   growth inhibitor, THP, ALB (abst) . . . . . 295  
   growth, Ca and K, Al effects . . . . . S-20  
   urinary calcium oxalate growth inhibitor . . . . . 829  
 Cuprophane dialysis membranes  
   generation of activated Hageman factor (abst) . . . . . 210  
 Cuprophane-induced hypertension (abst) . . . . . 227



- Cyclic AMP  
 cellular mechanism of hormone action in the kidney . . . . . 90  
 in dopamine receptors (abst) . . . . . 345  
 inositol
- phospholipid metabolism in mesangial cells (abst) . . . . . 347  
 metabolism and sites of action of vitamin D . . . . . 98  
 prostaglandins, alpha 2 adrenoceptors (abst) . . . . . 346  
 relaxation of cultured rat mesangial cells (abst) . . . . . 345  
 stimulated neutrophils on (abst) . . . . . 349
- Cyclophosphamide  
 daily administration, primary interstitial nephritis . . . . . 635  
 membranous glomerulonephritis (abst) . . . . . 274
- Cyclosporin A  
 acid secretion in turtle (abst) . . . . . 368  
 altered renal tubular cells in cytology (abst) . . . . . 1261  
 anti-thymocyte globulin for treatment of rejection  
 (abst) . . . . . 427  
 blood pressure in SHR (abst) . . . . . 251  
 blood transfusions and, in transplantation (abst) . . . . . 435  
 cadaveric renal transplantation (abst) . . . . . 612  
 calcium channel blocker inhibition (abst) . . . . . 307  
 cell proliferation in renal interstitium (abst) . . . . . 303  
 chronic adaptation to unilateral nephrectomy (abst) . . . . . 426  
 chronically instrumented dogs (abst) . . . . . 1262  
 conversion to Aza thioprine in renal allografts (abst) . . . . . 1261  
 corpulence index in dosage after transplantation (abst) . . . . . 1262  
 decrease in GFR is mediated by renal blood flow (abst) . . . . . 431  
 deposits in renal allograft (abst) . . . . . 612  
 erythromycin drug interaction (abst) . . . . . 438  
 exacerbates adriamycin-induced proteinuria (abst) . . . . . 434  
 glomerulonephritis . . . . . 182  
 induced hyperkalemia (abst) . . . . . 435  
 inhibits trypanosomiasis-induced nephrotic syndrome  
 (abst) . . . . . 36  
 lipid peroxidation in cortical mitochondria (abst) . . . . . 311  
 lymphocyte activation cascade . . . . . 613  
 nephrotoxicity (abst) . . . . . 303  
 nephrotoxicity in rat (abst) . . . . . 304  
 nephrotoxicity, intraluminal obstruction (abst) . . . . . 312  
 nephrotoxicity in Wistar rat (abst) . . . . . 1260  
 nephrotoxicity, urinary thromboxane (abst) . . . . . 304  
 peripheral lymphocytes (abst) . . . . . 1261  
 remission of NS (abst) . . . . . 206  
 rescue of rejecting transplant (abst) . . . . . 426  
 rheumatoid arthritis . . . . . 1180  
 serum urate level in transplantation (abst) . . . . . 426  
 sodium reabsorption (abst) . . . . . 304  
 stable renal transplant recipients (abst) . . . . . 437  
 systemic lupus erythematosus syndrome (abst) . . . . . 294  
 value of allograft biopsy in (abst) . . . . . 438  
 vasoconstriction in transplant recipients (abst) . . . . . 428
- Cyst  
 accelerated renal, development in germ-free rats . . . . . 1116  
 infection in ADPKD (abst) . . . . . 203  
 volume reduction in PKD (abst) . . . . . 179
- Cystic fibrosis  
 hospital-associated hyponatremia . . . . . 1237
- Cystine transport (abst) . . . . . 350
- Cystinuric, anti, and glutamine (abst) . . . . . 192
- Cystopathy, transplantation (abst) . . . . . 429
- Cytology  
 cyclosporine A altered renal tubular cells (abst) . . . . . 1261
- Cytomegalovirus glomerulopathy . . . . . 725
- Cytomegalovirus infection  
 mononuclear subset monitor (abst) . . . . . 944
- Cytoplasmic edema, injury in S3 tubule . . . . . 1033
- Cytosolic calcium and PTH (abst) . . . . . 175
- Cytotoxic T lymphocytes, MHC (abst) . . . . . 281
- C3 deposition causes hematuria (abst) . . . . . 274
- C3D deposits as marker in GLN (abst) . . . . . 1249
- D valine medium, assay (abst) . . . . . 353
- D, vitamin  
 metabolism and site in the kidney . . . . . 98
- Deconditioned germ-free rats, cyst . . . . . 1116
- Deferoxamine therapy  
 Al removal (abst) . . . . . 190  
 in CAPD, HD, HF (abst) . . . . . 171  
 kinetics (abst) . . . . . 226  
 Al removal (abst) . . . . . 190
- Deformylase activity, renal (abst) 361
- Degradation of insulin (abst) . . . . . 355
- Desferrioxamine  
 changes in bone histology after treatment . . . . . S-108  
 clearance of aluminum by hemodialysis . . . . . S-100  
 diagnosis of aluminum bone disease . . . . . S-96  
 dialysis encephalopathy . . . . . S-104
- Dexamethasone, sphingolipids (abst) . . . . . 334
- Dextran transfer, peritoneum (abst) . . . . . 232
- Diabetes  
 calcium and insulin (abst) . . . . . 314  
 compensatory renal growth, modulation by Ca PTH,  
 1,25(OH)2D3 . . . . . 1124  
 creatinine clearance in non-insulin-dependent (abst) . . . . . 179  
 cystopathy and successful kidney transplantation (abst) . . . . . 429  
 decreased gentamicin renal cortical uptake (abst) . . . . . 297  
 degradation of basement membrane (abst) . . . . . 1250  
 diet in type I (abst) . . . . . 195  
 elevated Al in CRF patients (abst) . . . . . 176  
 experimental, enhanced glomerular permeability (abst) . . . . . 264  
 experimental, hypertension in (abst) . . . . . 261  
 features in insulin-requiring (abst) . . . . . 611  
 GBM anionic sites, albumin excretion (abst) . . . . . 294  
 glomerular injury (abst) . . . . . 328  
 glucagon and PTH on juxtamedullary nephrons . . . . . 807  
 glucose control in (abst) . . . . . 196  
 glycemia, protein modulate GFR and albuminuria in  
 (abst) . . . . . 389  
 hemodialyzed, glycosylation not sole reason, low PTH  
 (abst) . . . . . 210  
 immunological  
 indomethacin on glomerular hemodynamics . . . . . 490  
 insipidus and AVP (abst) . . . . . 178  
 insulin therapy normalizes (abst) . . . . . 316  
 less PTH gland response to hypocalcemia in patients  
 (abst) . . . . . 159  
 mellitus, foot process width and filtration slit (abst) . . . . . 273  
 nephropathy, early uremic pericarditis (abst) . . . . . 186  
 nephropathy, hyperphagia (abst) . . . . . 324  
 nephropathy, insulin therapy (abst) . . . . . 325  
 NMR measures sodium in proximal tubules (abst) . . . . . 356  
 non-insulin dependent, elevated blood pressure (abst) . . . . . 183  
 parenchymal histological changes in ureteric ligation  
 (abst) . . . . . 296  
 phosphate depletion, proteinuria (abst) . . . . . 313  
 piroxicam (abst) . . . . . 611  
 prostaglandins, hyperfiltration (abst) . . . . . 332  
 proteinuria of type I and II influenced by BP (abst) . . . . . 189  
 reduced glomerular antiotensin II receptor density  
 (abst) . . . . . 327

- role of dietary protein (abst) . . . . . 289  
 streptozotocin-induced, HgCL<sub>2</sub> induced ATN (abst) . . . 308  
 streptozotocin-induced, tubular Na-K-ATPase (abst) . . . 410  
 Tamm-Horsfall glycoprotein biochemistry in (abst) . . . 1257  
 type I, glomerular filtration surface . . . . . 889  
 Diagnosis of renal disease  
   monoclonal antibodies in . . . . . 142  
 Dialysate  
   Al reduction in CAPD, Mg hydroxide, low Mg (abst) . . 232  
   calcium levels on BP during HD (abst) . . . . . 225  
   detrimental effect to increase bicarbonate (abst) . . . . 222  
   release of interleukin-1 during HD . . . . . 221  
   volume measurement (abst) . . . . . 236  
   volume on peritoneal mass transfer (abst) . . . . . 235  
 Dialysis  
   acetate vs. bicarbonate in ventilated patients (abst) . . . 944  
   Al on mineralization during matrix-induced bone development . . . . . 1038  
   aluminum metabolism . . . . . S-8  
   aluminum removal by microencapsulated carbon (abst) . 226  
   aluminum-induced encephalopathy, blood brain barrier (abst) . . . . . 610  
   anemia in patients with Al overload, desferrioxamine (abst) . . . . . 210  
   ARF in newborns, treatment by CAVH . . . . . 908  
   Austrian aluminum and renal bone disease . . . . . S-65  
   bicarbonate, predicting acetate intolerance (abst) . . . . 215  
   bowel infarction common in (abst) . . . . . 212  
   campylobacter pericarditis with effusion (abst) . . . . . 228  
   CAPD and initial modality (abst) . . . . . 235  
   cardiovascular response to hemofiltration . . . . . 901  
   children, different modalities effect on growth (abst) . . 233  
   children, features of renal bone disease (abst) . . . . . 236  
   concentric ventricular hypertrophy (abst) . . . . . 217  
   dementia, phosphate binding gels . . . . . 1131  
   diagnosis of aluminum bone disease . . . . . S-96  
   encephalopathy . . . . . S-53  
   encephalopathy, non-aluminum phosphate binding compound . . . . . S-120  
   encephalopathy, role of desferrioxamine in treatment . S-104  
   euthanasia, stopping chronic (abst) . . . . . 220  
   extreme hyperglycemia in (abst) . . . . . 200  
   hemofiltration without substitution fluid (abst) . . . . . 610  
   high vascular recirculation rates cause increase time (abst) . . . . . 219  
   home, removal of aluminum . . . . . 209  
   impoverished centers, aluminum contamination of water . . . . . S-58  
   membranes, activation of Hageman factor (abst) . . . . . 224  
   membranes, polymorphonuclear neutrophils (abst) . . . . 609  
   osteodystrophy, aluminum related bone disease . . . . . S-80  
   osteomalacia, natural course of . . . . . S-74  
   peritoneal, outbreak of group IV bacillus (abst) . . . . . 230  
   peritoneal, ultrafiltration maximum (abst) . . . . . 235  
   plasma transferrin after DFO, with, without Al intoxic (abst) . . . . . 225  
   platelet aggregation studies during (abst) . . . . . 221  
   primary renal transplantation before (abst) . . . . . 430  
   prostaglandin-mediated loss of proteins during peritonitis . . . . . 584  
   risk of peritonitis in acute care hospital (abst) . . . . . 238  
   role of plasma aluminum in toxicity . . . . . S-91  
   routine short (abst) . . . . . 210  
   schedule, nightly (abst) . . . . . 233  
   serum aluminum levels in patients (abst) . . . . . 165  
   transcapillary colloid osmotic gradient, body fluid volumes . . . . . 895  
   transplantation of ESRD from hypernephroma (abst) . . . 433  
   where are peritoneal membranes? (abst) . . . . . 236  
   C102 a non-noxious disinfectant (abst) . . . . . 227  
 Dialyzer  
   C102, neutropenia (abst) . . . . . 221  
   formaldehyde kinetics and bacteriology (abst) . . . . . 213  
   hollow fiber, variations (abst) . . . . . 222  
   membranes, removal of Al (abst) . . . . . 215  
   plate vs. hollow-fiber (abst) . . . . . 212  
   therapy for rapid high efficiency hemodialysis (abst) . . 215  
 Diaphragm, air under, CAPD (abst) . . . . . 233  
 Diatrizoate  
   on renal membranes (abst) . . . . . 302  
   precipitates membrane (abst) . . . . . 312  
 Dibutylryl cAMP, phosphate (abst) . . . . . 155  
 Dicyclohexylcarbodiimide (abst) . . . . . 369  
 Diet  
   Ca and K on bone calcium, phosphorous and density (abst) . . . . . 173  
   Ca<sup>2+</sup> in hypertension (abst) . . . . . 166  
   energy intake on nitrogen metabolism in CRF . . . . . 734  
   fasting, renal net acid excretion determines calcium . . 743  
   phosphate manipulation (abst) . . . . . 162  
   phosphorus-induced changes in 1,25(OH)<sub>2</sub>D<sub>3</sub> (abst) . . . 169  
   potassium as determinant of sodium excretion (abst) . . 182  
   protein limitation in type I diabetes (abst) . . . . . 195  
   protein restriction in diabetic nephropathy (abst) . . . . 209  
   risk, benefit of low-protein, essential amino acid . . . . 995  
   varying protein in hypertension . . . . . 520  
   varying protein levels, tubuloglomerular feedback . . . . 520  
 Diffuse proliferative lupus nephritis  
   renal histology correlates with outcome in children . . . 1066  
 Digitalis-like factors, excretion (abst) . . . . . 249  
 Digoxin antibodies, BP, SHR (abst) . . . . . 252  
 Diltiazem monotherapy (abst) . . . . . 259  
 Diluting segment, Bartter's Syn (abst) . . . . . 416  
 Dipeptides, transport, metabolism (abst) . . . . . 1234  
 Dipyrindamole  
   and vasodilation (abst) . . . . . 184  
   ischemic ARF (abst) . . . . . 305  
 Disease, chronic renal, Bright's . . . . . 779  
 Disinfectant in dialyzer (abst) . . . . . 227  
 Distal nephron segments  
   regulation of renal acid secretion . . . . . 1099  
   rubidium (abst) . . . . . 391  
 Diuresis  
   atriopeptin II induced, dopamine, α<sub>2</sub>-adrenoceptor (abst) . . . . . 395  
   PK of bicarbonate at low, high concentrations (abst) . . 377  
   forced (abst) . . . . . 191  
 Diuretic  
   abnormal renal hemodynamics in rat (abst) . . . . . 257  
   effects of on mineral contents of kidney and femur (abst) . . . . . 160  
   hyponatremia, new formula for correction of (abst) . . . 203  
   kallikrein-kininogen-kinin system (abst) . . . . . 330  
   prolonged furosemide administration (abst) . . . . . 208  
   torasemide (abst) . . . . . 1254  
 Docpivalate treated, intercalated (abst) . . . . . 372  
 Donor  
   living non-related kidney, for transplantation (abst) . . . 430  
   long-term blood pressure and renal function in kidney . 1072

- Dopamine  
atrial natriuretic peptide (abst) . . . . . 336  
cAMP accumulation (abst) . . . . . 345  
proximal convoluted tubule NaKATPase activity (abst) . . 390  
receptors, hypertensive (abst) . . . . . 245  
renal hemodynamics during infusion of, and amino acids . . . . . 870  
renal-adrenal responses to blockade of (abst) . . . . . 194  
2 receptor in canine kidney (abst) . . . . . 385  
receptors, hypertensive (abst) . . . . . 245  
1 agonist, hemodynamics (abst) . . . . . 333
- Doppler  
measurement in grafts (abst) . . . . . 217  
method, noninvasive for renal blood flow measurement (abst) . . . . . 379
- Drug abusers, hemodialysis (abst) . . . . . 223  
Drug sieving coefficients, CAVH (abst) . . . . . 214  
Dyspnea, lactic acidosis . . . . . 752
- Early renal failure, phosphate (abst) . . . . . 609
- Edema  
prognosis and treatment of membranous nephropathy . . 927  
CAVH for heart failure (abst) . . . . . 226
- Efferent vasodilation  
antiproteinuric effect of dipyridamole (abst) . . . . . 184
- Eicosanoids  
Heymann Nephritis (abst) . . . . . 344  
permeability in CAPD (abst) . . . . . 237
- Eicosapentaenoic acid (abst) . . . . . 311, 325
- Elalapril, parenchymal HT (abst) . . . . . 256
- Electrical charge  
antibody, antigen, glomerular capillary wall charge . . . 649
- Electrical properties, duct (abst) . . . . . 1234
- Electrodense deposit in SLE (abst) . . . . . 273
- Electrolyte  
concentrations, renal cortex under K adaptation (abst) . 1203  
dietary, dissociation of renin and aldosterone (abst) . . . 410  
hospital-associated hyponatremia . . . . . 21  
humoral control of water and, excretion . . . . . 1152
- Electron microscopy  
light chain deposition disease defined (abst) . . . . . 288
- Electrophysiological, renal cells (abst) . . . . . 391
- Electrophysiology amphiuma CT (abst) . . . . . 398
- Electrothermal determination of Al . . . . . S-28
- Enalapril blocks albinuria (abst) . . . . . 320
- Enalaprilat hemodynamics (abst) . . . . . 243
- Enalaprilic acid, renal response (abst) . . . . . 944
- Enalapril, Bartter syndrome (abst) . . . . . 190
- Encephalopathy  
aluminum-induced, blood brain barrier (abst) . . . . . 610  
associated with aluminum accumulation . . . . . S-70  
hyponatremia (abst) . . . . . 177  
role of plasma aluminum in toxicity . . . . . S-91
- End stage renal disease  
atrial natriuretic peptide in plasma of children (abst) . . 1254  
beta 2 adrenoceptor stimulated potassium (abst) . . . . . 324  
cadaveric renal transplantation (abst) . . . . . 942  
childhood membranoproliferative glomerulonephritis . . 1077  
children, caloric intake to erythrocyte insulin (abst) . . . 177  
children, successful hemofiltration (abst) . . . . . 221  
cholesterol metabolism (abst) . . . . . 224  
cholesterol metabolism in (abst) . . . . . 224  
comparative effects of Al, CaCO<sub>3</sub>, K balance (abst) . . . 219  
creatinine kinase and lactate dehydrogenase isoenzymes (abst) . . . . . 212
- desferrioxamine in dialysis encephalopathy treatment . . S-104  
diagnosis of myocardial infarction (abst) . . . . . 185  
effects of age and, on lymphocyte mitogenic response (abst) . . . . . 229  
erythropoietin levels in children, CAPD/CCPD vs. HD (abst) . . . . . 229  
features of hypothyroidism (abst) . . . . . 192  
hepatitis B viral infection in (abst) . . . . . 195  
hyperlipasemia and hyperamylasemia (abst) . . . . . 217  
hypertensive in large population (abst) . . . . . 197  
individual prognosis of IgA nephropathy . . . . . 549  
infants managed with CPD and NG (abst) . . . . . 230  
left ventricular failure in (abst) . . . . . 220  
less PTH gland response to hypocalcemia in diabetics (abst) . . . . . 159  
sodium transport in red blood cells of dialyzed . . . . . 1197  
stress program for patients (abst) . . . . . 201  
treatment incidence rates by state (abst) . . . . . 201
- Endocytosis, endosomes (abst) . . . . . 420  
receptor-mediated (abst) . . . . . 254
- Endothelial  
acetylcholine (abst) . . . . . 256  
cells release platelet-activating factor . . . . . 469  
cell binding (abst) . . . . . 264  
in acetate (abst) . . . . . 215  
microvascular, IL-1 (abst) . . . . . 275
- Endotoxemic ARF (abst) . . . . . 306
- Endotoxin induction, interleukin (abst) . . . . . 219
- Energy metabolism, NH<sub>4</sub><sup>+</sup> (abst) . . . . . 352
- Enkephalin degrading enzyme (abst) . . . . . 271
- Enzyme inhibitor  
renal response to (abst) . . . . . 944
- Enzymes and aluminum . . . . . S-12
- Enzymes, serine proteases, kallikrein . . . . . 953
- Eosinophilia, peritoneal (abst) . . . . . 231
- Eosinophiluria, detection of (abst) . . . . . 198
- Epithelia  
A6, Cl secretion (abst) . . . . . 411  
cultured renal . . . . . 49  
cyst-derived PKD (abst) . . . . . 323  
fusion, study cell mechanisms of ion transport (abst) . . 404  
hyperplastic in ADPKD (abst) . . . . . 276  
leaky, mucosal calcium removal on (abst) . . . . . 422  
membrane properties of fused (abst) . . . . . 1251  
permeability of inner medullary collecting duct (abst) . . 418  
12-HETE (abst) . . . . . 335
- Epitope, antibodies for Tamm-Horsfall . . . . . 971
- Epitrochlearis muscle, insulin (abst) . . . . . 316
- Erosive dialysis arthropathy (abst) . . . . . 229
- Erythrocyte  
clearing mechanism (abst) . . . . . 277  
electrophoretic analysis of protein composition (abst) . . 242  
morphology in urine (abst) . . . . . 1258
- Erythromycin  
CyA drug interaction (abst) . . . . . 438
- Erythropoiesis  
aluminum (abst) . . . . . 610
- Erythropoietin production (abst) . . . . . 167
- Ethacrynic acid  
hypernatremia inhibits NaHCO<sub>3</sub> reabsorption . . . . . 820
- Ethane, lipid peroxidation (abst) . . . . . 308
- ETO antibody response (abst) . . . . . 266
- Euthanasia, passive, dialysis (abst) . . . . . 220
- Exchanger  
basolateral, in volume (abst) . . . . . 398



- Na/H in hypertensive (abst) ..... 245
- Excretion
- artifactual endogenous digitalis-like factors (abst) ..... 249
  - biliary conjugated small molecular wt compounds (abst) ..... 317
  - humoral control of water and electrolyte during restriction ..... 1152
  - of Pi by PFA (abst) ..... 174
  - potassium, chronic K loading in man (abst) ..... 1251
- Exercise
- impairment a characteristic of HD (abst) ..... 223
  - post-transplantation (abst) ..... 434
  - protein excretion (abst) ..... 191
- Exocytosis, pH, H<sup>+</sup> ATPase (abst) ..... 378
- Extracellular matrix
- modulates mesangial cell behavior (abst) ..... 275
- Eye chamber, transplant of kidney cells ..... 1234
- Failure, renal
- loop diuretic muzalimine in hypertensive (abst) ..... 1255
  - protection form acute ischemic (abst) ..... 1254
  - risk, benefit of low protein-essential amino acid diet ... 995
  - with nifedipine (abst) ..... 778
- Fasting
- urinary calcium excretion, renal net acid excretion ... 743
- Fc receptor in cryoglobulinemia (abst) ..... 608
- Feeding, chronic alternate day (abst) ..... 319
- Fenoldopam, protein feeding (abst) ..... 313
- Ferritins, polymeric in GBM (abst) ..... 1248
- Fibronectin
- concentration, CAPD (abst) ..... 232
  - reduced binding (abst) ..... 267
- Filtration
- renal reserve in pregnant rats, acute glycine (abst) .... 380
- Filtration fraction
- infusion of dopamine, amino acids on renal hemodynamics ..... 870
  - superficial nephron ..... 814
- Filtration rate, GLN (abst) ..... 322
- Fluorescent markers, ADH bladder (abst) ..... 416
- Fluorocitrate, metabolism in dog (abst) ..... 353
- Fluorescent probe, HCO<sub>3</sub> (abst) ..... 371
- Focal glomerular sclerosis
- converting enzyme inhibition ..... 265
  - (abst) ..... 200
- Focal segmental glomerulosclerosis
- (abst) ..... 275
  - global (abst) ..... 179
  - prognosis of in adults (abst) ..... 193
- Formate, NaCl transport (abst) ..... 407
- Fragmentation, injury in S3 tubule ..... 1033
- Free radical
- damage in ischemic ARF, hypothyroidism ..... 1162
- Fuels
- metabolic along the nephron, mechanisms of interaction ..... 41
- Function, renal
- ionized calcium modulates (abst) ..... 381
- Fura 2, Quin 2 measurement Ca<sup>2+</sup> (abst) ..... 399
- FURA-2, Ca measurement (abst) ..... 335
- Furosemide
- K<sup>+</sup> efflux in proximal tubule (abst) ..... 396
  - natriuresis, atrial natriuretic factor (abst) ..... 398
  - natriuretic response during prolonged administration (abst) ..... 208
  - nephron response (abst) ..... 180
  - PGE2 (abst) ..... 337
- Gap junctions, LLC PK1 (abst) ..... 404
- Gasoline injection, renal injury (abst) ..... 304
- GC/MS isotope dilution, in assay (abst) ..... 202
- Gelifundol, polyelectrolyte (abst) ..... 230
- Genetic hypertension, suckling, BP(abst) ..... 241
- Genetic variability to Ca (abst) ..... 247
- Genomic mechanism
- vitamin D and the kidney ..... 98
- Gentamicin
- bacteremia nephrotoxic synergy (abst) ..... 313
  - calcium abnormalities in renal proximal tubules (abst) .. 298
  - decreased renal cortical uptake in diabetic (abst) ..... 297
  - phosphatidylinositol cascade (abst) ..... 308
  - phospholipidosis (abst) ..... 311
- Geochemistry of aluminum ..... S-3
- Germ-free rats, cyst development ..... 1116
- GFR, cirrotics no increase (abst) ..... 185
- Gibbsite
- phosphate binder gels balance adsorption, Al toxicity . 1131
- Glandular kallikrein ..... 120
- Glomerular
- action leukotriene D4 (abst) ..... 328
  - AII density reduced (abst) ..... 327
  - barrier colloid volume expansion ..... 916
  - capillary wall, antibody, antigen charge interactions ... 649
  - crescents, epithelial origin (abst) ..... 278
  - function, protein intake (abst) ..... 325
  - hemodynamic alterations in Heymann Nephritis (abst) . 383
  - morphologic changes, proteinuria-role of oxygen free radical ..... 478
- Glomerular basement membrane
- degradation by PMA-stimulated neutrophils (abst) .... 291
  - deposition of cationised ferritins in (abst) ..... 1248
  - nephrotic plasma increases proteinuria (abst) ..... 295
- Glomerular capillary hypertention (abst) ..... 244
- Glomerular cells
- culture and characterization of mesangial (abst) ..... 944
- Glomerular charge barrier ..... 270
- Glomerular disease
- progressive, adriamycin-induced nephropathy ..... 502
- Glomerular
- complement depletion in passive Heymann Nephritis (abst) ..... 380
  - dynamics, PG2 and PGI2 (abst) ..... 334
  - thyroid (abst) ..... 318
  - epithelial cell, DM (abst) ..... 273
  - epithelial cells (abst) ..... 277
  - epithelial, cloning (abst) ..... 279
  - epithelium murine Ia alloantigen (abst) ..... 294
  - lesions in LGN (abst) ..... 196
  - mesangial cells, thromboxane A2 (abst) ..... 340
  - permeability, experimental diabetic nephropathy (abst) . 264
  - permeability, MVE-2 nephropathy (abst) ..... 265
  - polyanion complex (abst) ..... 285
  - prostaglandins, thromboxane synthesis in hypertension (abst) ..... 610
  - prostanoid synthesis (abst) ..... 339
  - sclerosis, focal segmental, prognosis in adults (abst) ... 193
  - visceral epithelial cells (abst) ..... 339
- Glomerular filtration rate
- aspirin prevents reduced (abst) ..... 323
  - atrial natriuretic factor increases (abst) ..... 332

- atrial natriuretic factor induce natriuresis (abst) . . . . . 402  
 biology of renal hypertrophy . . . . . 619  
 cAMP excretion, adenosine analogs effect on (abst) . . . . . 358  
 glycemia and dietary protein modulate (abst) . . . . . 389  
 hemodynamics during infusion of amino acids, dopa-  
 mine. . . . . 870  
 infusion of amino acid, dopamine on renal hemody-  
 namics . . . . . 870  
 protein loading on remnant rat kidney (abst) . . . . . 324  
 surface in type I diabetes mellitus . . . . . 889  
 synthetic atrial natriuretic peptide (abst) . . . . . 393  
 transplant patients receiving cyclosporine (abst) . . . . . 428  
 tubuloglomerular feedback control of (abst) . . . . . 388  
 tubuloglomerular feedback during volume expansion  
 (abst) . . . . . 1253  
 utility of 125I iothalamate clearance as marker (abst) . . . 188
- Glomerular injury**  
 antihypertensive therapy, dietary protein (abst) . . . . . 319  
 prevention in diabetes mellitus (abst) . . . . . 328
- Glomeruli**  
 mesangial, renin (abst) . . . . . 331  
 nephritic, cytotoxic (abst) . . . . . 283
- Glomerulonephrids**  
 non immunological mechanisms in progressions (abst) . 1250
- Glomerulonephritis**  
 anti-GBM, auto-anti-idiotypic antibodies in (abst) . . . . . 290  
 autoimmune, induced by mercuric chloride (abst) . . . . . 608  
 autoregulate filtration rate (abst) . . . . . 322  
 canine chronic renal disease, prevalence and types . . . 1144  
 childhood membranoproliferative. . . . . 1077  
 children, acute sporadic poststreptococcal (abst) . . . . . 178  
 crescentic (abst) . . . . . 189  
 cyclosporine treatment of patients with (abst) . . . . . 182  
 C3d deposits as marker of complement activation  
 (abst) . . . . . 1249  
 C5 complement (abst) . . . . . 274  
 experimental autoimmune, T cells (abst) . . . . . 269  
 idiopathic membranous, IgG subclasses (abst) . . . . . 287  
 IgA synthesis by lymphocytes from patients, their rela-  
 tives . . . . . 1229  
 IgA, antigliadin antibodies in (abst) . . . . . 776  
 immune complex, role of lymphocytes (abst) . . . . . 1249  
 immune complex, thromboxane B2 formation  
 immune-complex-mediated, scanning electron micros-  
 copy (abst) . . . . . 282  
 in ANF negative SLE with low complement (abst) . . . 1256  
 malarial (abst) . . . . . 280  
 membranoproliferative, anti-idiotypic to C3NEF (abst) . 292  
 membranoproliferative in renal transplants . . . . . 429  
 membranoproliferative, alternate complement pathway  
 (abst) . . . . . 278  
 minimal change, focal sclerosis, MHC antigens (abst) . . 286  
 minimal change, HLA-DR7 and MT3 association  
 monoclonal anti-rat-thymocyte antibodies (abst) . . . . . 945  
 myeloperoxidase-hydrogen peroxide-halide system  
 (abst) . . . . . 278  
 necrotizing, protease inhibitor amelioration (abst) . . . . . 275  
 neutrophil-mediated (abst) . . . . . 271  
 proliferative, immune deposits in AIDS (abst) . . . . . 272  
 proliferative, T cells in crescentic (abst) . . . . . 267  
 pulse methylprednisolone therapy (abst) . . . . . 180  
 rapidly progressive, long term follow-up (abst) . . . . . 181  
 role of lymphocytes (abst) . . . . . 292  
 subtypes of acute postinfectious (abst) . . . . . 1250  
 transition from proliferative to membranous, serum  
 sickness . . . . . 841  
 1- and 12-hydroperoxyeicosatetraenoic acid (abst) . . . . 339
- Glomerulopathy**  
 crescentic, identification (abst) . . . . . 775  
 cytomegalovirus, lesions . . . . . 725  
 giant fibrillar deposits in renal transplants (abst) . . . . 1262  
 proliferative, analysis of extra-cellular granular (abst) . . 775
- Glomerulosclerosis**  
 focal and segmental study (abst) . . . . . 275  
 focal segmental, early lesion (abst) . . . . . 437  
 FGS (abst) . . . . . 179  
 focal (abst) . . . . . 200  
 focal  
 segmental, genetic factors . . . . . 789  
 focal, tubuloglomerular feedback of rats on varying  
 protein . . . . . 520  
 progressive, high dietary protein in dogs . . . . . 511  
 proteinuria, prevention of by hypertension (abst) . . . . . 281  
 transgenic mouse model (abst) . . . . . 283
- Glomerulus**  
 degradation of diabetic, nondiabetic basement  
 membrane(abst) . . . . . 1250  
 immunocytochemical localization of renin and  
 kallikrein . . . . . 965  
 prognosis and treatment of membranous nephropathy . . 927
- Glucagon**  
 PTH effect on loop of Henle juxtamedullary nephrons . . 807  
 tubular effects in man (abst) . . . . . 413
- Glucocorticoid**  
 cytosolic (abst) . . . . . 352  
 metabolites effect on membrane transport (abst) . . . . . 358  
 pressor response (abst) . . . . . 246  
 sodium (abst) . . . . . 330  
 transcription of interleukin 1-encoding RNA (abst) . . . . 431
- Gluconeogenesis**  
 ammoniagenesis, 13C NMR and 15N GC-MS (abst) . . . . 357  
 LLC-PK1 cells (abst) . . . . . 354  
 nerve stimulation (abst) . . . . . 349  
 phosphinositide metabolism regulation (abst) . . . . . 353
- Glucose**  
 metabolism in renal tubular function . . . . . 54  
 reabsorption increased in POK (abst) . . . . . 330  
 transporters in intestine (abst) . . . . . 423
- Glutamine**  
 anticystinuric effect (abst) . . . . . 192  
 homeostasis in metabolic acidosis (abst) . . . . . 365  
 nitrogen (abst) . . . . . 350  
 plasma concentration, renal ammoniagenesis (abst) . . . . 351  
 regulation of metabolism in dog kidney . . . . . 68  
 uptake, effect of acivicin (abst) . . . . . 359
- Glutathione**  
 depletors, proximal tubules . . . . . 858  
 in proximal tubule (abst) . . . . . 310
- Glycerophosphorylcholine (abst) . . . . . 1234**
- Glycine**  
 infusion, renal reserve in pregnant rats (abst) . . . . . 380
- Glycolysis**  
 phorbol myristate acetate stimulates (abst) . . . . . 338
- Glycoprotein**  
 ALDO, in toad (abst) . . . . . 351  
 isolation of inhibitor from calcium oxalate stones (abst) . . 167  
 laminin, antibodies to in preeclampsia . . . . . 1050  
 cellular physiology of glandular kallikrein . . . . . 953
- Glycosylation, low PTH in diabetic(abst) . . . . . 210**

- Gold-insulin  
luminal uptake and transport ..... 983
- Goodpasture antigen in Alport's (abst) ..... 202
- Goodpasture syndrome  
autoantibody subclass restriction (abst) ..... 287  
post-mycoplasma-pneumonia infection (abst) ..... 1256
- Graft survival, risk factors (abst) ..... 434
- Gram negative peritonitis, assay (abst) ..... 239
- Granular material, PGN (abst) ..... 775
- Granulomatosis, Wegener's (abst) ..... 185
- Gravity, urine specific, neonates (abst) ..... 177
- Growth  
biology of renal hypertrophy ..... 619  
compensatory renal, modulation by Ca PTH and 1,25-(OH)<sub>2</sub>D<sub>3</sub> ..... 1124
- Guanabenz  
natriuretic antihypertensive drug ..... 1203
- Guanine nucleotide, protein (abst) ..... 333
- H-pump, electrochemical potential (abst) ..... 369
- H<sup>+</sup>ATPASE reconstitution (abst) ..... 366
- Hageman factor  
activation (abst) ..... 224  
by cuprophane dialysis membrane ..... 210
- Hansel's staining technique (abst) ..... 198
- Heart  
artificial, ANP levels (abst) ..... 192  
disease, phlebotomies (abst) ..... 776  
failure, modulation of vasopressin by cardiac function ..... 1188
- Hematologic malignancies (abst) ..... 187
- Hematopoiesis  
effect of aluminum on ..... S-45  
transplantation (abst) ..... 427
- Hematuria  
childhood membranoproliferative glomerulonephritis .. 1077  
hypercalciuria in children with (abst) ..... 204  
red cell morphology (abst) ..... 201  
states, lysis (abst) ..... 183
- Hemodiafiltration, high flux, 1 yr(abst) ..... 227
- Hemodialysis  
acetate intolerance during (abst) ..... 223  
acidosis and anion gap prior to (abst) ..... 197  
age and HD effect lymphocyte mitogenic response (abst) ..... 229  
aluminum and porphyrin metabolism in (abst) ..... 211  
aluminum removal by (abst) ..... 215  
aluminum toxicity in prolonged (abst) ..... 211  
amyloidosis in population of 250,000 (abst) ..... 777  
anabolism in subset of "nourished" (abst) ..... 209  
anemia in long-term (abst) ..... 214  
blood from arterial lines for gas analysis (abst) ..... 943  
blood membrane contact, circulation (abst) ..... 1260  
body composition changes in (abst) ..... 222  
changing pattern and outcome of ARF ..... 176  
clearance of aluminum, desferrioxamine ..... S-100  
clinical, biological features of Al-related bone disease . S-80  
dialysate calcium levels on BP (abst) ..... 225  
end stage lupus nephritis, poor prognosis (abst) ..... 183  
exercise impairment characteristic (abst) ..... 223  
hematopoiesis, effect of aluminum on ..... S-45  
hematopoietic inhibitors in chronic renal failure ..... 641  
hepatitis B antigenemia in (abst) ..... 216  
hepatitis B vaccination, seroconversion (abst) ..... 1260  
high bicarbonate dialysate, acid-base, respiratory (abst) .. 220  
hypertriglyceridemia factors (abst) ..... 327  
i.v. drug abusers do well (abst) ..... 223  
impaired immune responses in CRF, T cell defect .... 1209  
influence of membrane biocompatibility (abst) ..... 225  
interleukin 1 in allergic reactions during (abst) ..... 608  
lactate/acetate buffer base cocktail for (abst) ..... 220  
leaching of plasticizer from PVC tubing in (abst) ..... 217  
leukocyte C5a receptor modulation (abst) ..... 281  
limulus amebocyte lysate reactive material (abst) ..... 211  
lipid and lipoprotein metabolism regulation (abst) ..... 222  
luteinizing hormone in men on maintenance (abst) ..... 225  
lymphocyte ATP (abst) ..... 327  
maintenance, mortality risk (abst) ..... 228  
membranes, comparative clearances (abst) ..... 228  
method for measuring aluminum ..... S-24  
modified, effect of on myocardial function, Ca level (abst) ..... 212  
non-invasive Doppler measurement of flow (abst) ..... 217  
osteodystrophy, disability and bone Al in patients (abst) ..... 168  
osteomalacia, aluminum-induced ..... S-17  
PAVP respond to decline in osmolality during (abst) ... 203  
rapid high efficiency therapy (abst) ..... 215  
release of interleukin-1 during (abst) ..... 221  
role of plasma aluminum in toxicity ..... S-91  
routine short (abst) ..... 210  
silastic catheters, internal jugular vein cannulation (abst) ..... 778  
strategies to reduce hypotension in unstable (abst) .... 224  
subclavian catheters, complications (abst) ..... 226  
transcapillary colloid osmotic gradient, renal failure ... 895  
trends of azotemia after chronic (abst) ..... 224  
uremic symptoms at start (abst) ..... 176  
vitamin K disorders induce vascular calcification (abst). 213  
vs. CAPD/CCPD in children, erythropoietin levels (abst) ..... 229  
99mTc-methylene diphosphonate bone scan in osteodystrophy ..... 1058
- Hemodynamics  
abnormal renal, pressure diuresis response in rat (abst). 257  
consequences of CAVH (abst) ..... 218  
glomerular injury, preglomerular resistance in hypertension ..... 849  
intermittant feeding (abst) ..... 319  
natriuresis induced by dopamine-1 agonist (abst) ..... 333  
renal, during infusion of amino acids and dopamine. ... 870
- Hemofilter, polysulfone (abst) ..... 216
- Hemofiltration  
arterio-venous, ARF in newborns ..... 908  
ESRD children (abst) ..... 221  
heterogeneity of cardiovascular response to ..... 901  
without substitution fluid (abst) ..... 610
- Hemoglobin, bovine on renal (abst) ..... 301
- Hemolytic uremic syndrome (abst) ..... 204
- Hemoperfusion  
hemodialysis, effective in methotrexate overdose (abst) .. 216  
hepato-renal syndrome managed by CAVH (abst) ..... 216
- Hemophilia, lactic acidosis ..... 752
- Hemorrhage, sulindac sulfide in plasma ..... 484
- Heparin sulfate proteoglycans (abst) ..... 283
- Heparin in AN (abst) ..... 273
- Hepatic  
congestion mechanism of altered renal function (abst) .. 385  
dysfunction, transplant (abst) ..... 438  
encephalopathy ..... 598  
GLN homeostasis (abst) ..... 370



- nephropathy (abst) ..... 285  
 veno-occlusive disease (abst) ..... 435  
**Hepatitis**  
   B in ESRD patients (abst) ..... 195  
   chronic B antigenemia in HD (abst) ..... 216  
   seroconversion rate in hemodialysis, zinc substitution(abst)..... 1260  
**Hepato-renal syndrome, CAVH (abst) ..... 216**  
**Hereditary**  
   regionalization in IgA nephropathy (abst) ..... 209  
**Heroin abuser, amyloidosis in (abst)..... 187**  
**Herpes virus, CMV ..... 725**  
**Hexose monophosphate shunt (abst)..... 338**  
**Heymann nephritis**  
   antigen antibody interactions (abst)..... 608  
   chlorpromazine inhibits antigens (abst) ..... 268  
   clone of glomerular visceral epithelial cells (abst)..... 279  
   cloning of glomerular visceral epithelial cells (abst) .... 279  
   glomerular hemodynamic alterations (abst)..... 383  
   glomerular hemodynamics, complement depletion (abst) ..... 380  
   inhibits subepithelial immune deposit formation (abst) .. 264  
   nephritogenicity of 70KD subunit (abst) ..... 291  
   newborn, transplacental transfer of autoantibodies (abst) ..... 284  
   protein modulates GFR of eicosanoids (abst) ..... 344  
   subepithelial electron dense immune deposit (abst) .... 269  
   two antigen-antibody systems (abst) ..... 263  
   60kDa duplet polypeptide, antigenic determinant (abst) 279  
**High flux hemodiafiltration, 1 yr (abst)..... 227**  
**Histidine, prostaglandin (abst)..... 331**  
**HLA-DR antigens**  
   renal allograft rejection (abst) ..... 944  
**HLA-DR7, MT3 association in MCGN (abst)..... 1249**  
**Hormone**  
   acute effects of ANF in man (abst) ..... 1253  
   cellular mechanism in the kidney ..... 90  
   humoral control of water and electrolyte excretion ... 1152  
   metabolic adaptations in renal disease ..... 80  
   modulation by verapamil ..... 863  
   systems and kallikrein-kinin system ..... 120  
   vasoactive to sepsis (abst) ..... 300  
   1,25-dihydroxyvitamin D3 step in action of (abst) .... 156  
**Hyalinosis, focal-segmental (abst)..... 197**  
   genetic factors in FGS ..... 789  
**Hydrochlorothiazide, CaSF (abst)..... 775**  
**Hydrogen**  
   ion secretion in distal nephron segments..... 1099  
   ion (H<sup>+</sup>) secretion by mesonephric collecting duct (abst) ..... 376  
**Hydrogen peroxide**  
   myeloperoxidase, -halide system (abst)..... 278  
   PGE2 (abst) ..... 291  
**Hydronephrosis, hypertension (abst) ..... 261**  
**Hydroxyapatite**  
   aluminum effect on calcium phosphate precipitation .... S-20  
**Hydroxylase complex, PTH (abst) ..... 171**  
**Hymphocytes, transferrin receptor (abst)..... 294**  
**Hyperactivity, B cell in Iga nephropathy ..... 718**  
**Hyperalbuminemic encephalopathy (abst) ..... 178**  
**Hypercalcemia**  
   aluminum related bone disease..... S-80  
   chronic liver disease (abst)..... 188  
   effect on urinary concentrating ability (abst)..... 423  
   hypertension, PTH (abst)..... 248  
   impairment of phosphate reabsorption in tubule (abst) .. 163  
   role of loop segment in urinary concentrating defect of . 977  
**Hypercalciuria**  
   in children (abst)..... 204  
   prolactin excess (abst) ..... 157  
   tubulopathy in nephrolithiasis ..... 563  
   urinary calcium and Ca intake during calcitriol ..... 578  
**Hyperchloremic metabolic acidosis**  
   urine anion gap valuable diagnostic tool..... 188  
**Hyperfiltration**  
   diet induced, glomerular vasodilatory prostaglandins (abst) ..... 343  
   glomerular filtration surface in type I diabetes ..... 889  
   indomethacin on protein induced glomerular (abst) .... 942  
   infusion of amino acids, dopamine on renal hemodynamics ..... 870  
**Hyperglycemia**  
   in dialysis (abst) ..... 200  
   induces Na and K retention (abst)..... 417  
   macula densa feedback (abst) ..... 389  
**Hyperkalemia**  
   cyclosporine Ac-induced (abst) ..... 435  
**Hyperlipidemia, CRF (abst)..... 326**  
**Hyperlipimia, albuminuria (abst)..... 193**  
**Hypernatremia**  
   hypovolemic humoral control of H<sub>2</sub>O, electrolyte excretion ..... 1152  
   inhibits NaHCO<sub>3</sub> reabsorption..... 820  
   in elderly (abst)..... 204  
**Hyperoncotic albumin, AII to ANP (abst) ..... 340**  
**Hyperosmolarity**  
   phorbol esters on cation fluxes in mTALH (abst)..... 395  
**Hyperparathyroidism**  
   biogenesis (abst) ..... 166  
   in early CRF (abst)..... 155  
   post-transplant treatment with APD biophosphonate (abst) ..... 941  
   renal mass major determinant of (abst) ..... 199  
   secondary, natural course of dialysis osteomalacia .... S-74  
   secondary (abst) ..... 164  
   treatment with APD, new biphosphonate (abst) ..... 1266  
   tubulopathy in nephrolithiasis ..... 563  
   uremia, calcium carbonate controls ..... S-14  
**Hyperperfusion, high protein diet in dog ..... 511**  
**Hyperphagia, diabetic (abst) ..... 324**  
**Hyperphosphatemia**  
   calcium carbonate Al-free agent for control in uremia .. S-114  
   (abst) ..... 174  
**Hyperpolarization, Ca loss (abst) ..... 393**  
**Hypersensitivity, delayed (abst) ..... 280**  
**Hypertensinogen 19-OH, 19-NOR (abst)..... 242**  
**Hypertension**  
   abnormal vitamin D in SHR (abst) ..... 247  
   ACE-inhibition (abst) ..... 945  
   adult-onset minimal change nephrotic syndrome. .... 1215  
   ANF and renal kallikrein-kinin systems (abst) ..... 1254  
   aortic coarctation, renal function (abst)..... 258  
   arresting progressive renal disease, drugs (abst)..... 314  
   atenolol decreases renal blood flow in (abst)..... 205  
   atrial natriuretic factor in salt-sensitive (abst)..... 334  
   arresting progressive renal disease, drugs (abst)..... 314  
   bone density (abst) ..... 205  
   BP control in normotensive members of hypertensive families ..... 882  
   calcium antagonists, renal and metabolic effects (abst) . 241  
   calcium channel abnormality (abst) ..... 259

- calcium, increased intestinal and renal in (abst) . . . . . 244  
 calcium, stress in (abst) . . . . . 247  
 calcium supplementation, effect in aorta of (abst) . . . . . 242  
 captopril-enhanced renal flow study (abst) . . . . . 254  
 cell membrane Na/H exchanger in spontaneously (abst) . . . . . 245  
 converting enzyme inhibition in (abst) . . . . . 255  
 dietary calcium supplementation (abst) . . . . . 241  
 effects of antihypertensive treatment . . . . . 1011  
 emergency, nifedipine in (abst) . . . . . 243  
 emergency, nifedipine in (abst) . . . . . 243  
 end-stage renal disease in large population (abst) . . . . . 197  
 essential, treated with diltiazem improves (abst) . . . . . 259  
 experimental diabetes in rat (abst) . . . . . 261  
 genetic factors in focal segmental glomerulosclerosis . . . . . 789  
 glomerular injury, preglomerular resistance in . . . . . 849  
 glomerular prostaglandins, thromboxane synthesis  
 (abst) . . . . . 610  
 Goldblatt, glomerular pressure and flow (abst) . . . . . 260  
 guanabenz, natriuretic antihypertensive drug . . . . . 1203  
 halides as determinant of Na<sup>+</sup> (abst) . . . . . 250  
 head-out water immersion, naloxone (abst) . . . . . 1259  
 hemodynamic effects of vasodilator therapy for (abst) . . . . . 175  
 hereditary in dogs (abst) . . . . . 242  
 hydronephrosis, parallel (abst) . . . . . 261  
 increased 18-OH-B and adrenal adenoma (abst) . . . . . 1259  
 individual prognosis of IgA nephropathy . . . . . 549  
 infants, prejuvenile, juveniles (abst) . . . . . 240  
 intracellular free calcium (abst) . . . . . 250  
 long-term blood pressure and renal function in donors . . . . . 1072  
 magnesium metabolism in SHR (abst) . . . . . 262  
 Na/K pump inhibition, reduced renal mass not produce  
 (abst) . . . . . 253  
 NaCl-sensitive in man, dietary chloride determines  
 (abst) . . . . . 250  
 neonatal drug treatment (abst) . . . . . 246  
 neurogenic mechanisms (abst) . . . . . 256  
 oxidative metabolism of cortical renal tubules (abst) . . . . . 242  
 parenchymal, renal, enalapril effect on (abst) . . . . . 256  
 plasma polypeptides in pre- (abst) . . . . . 260  
 potassium antihypertensive effect (abst) . . . . . 255  
 pregnancy, excretion of prostaglandin (abst) . . . . . 777  
 pregnancy, renin angiotensin aldosterone system (abst) . . . . . 777  
 pressure-natriuresis relationship (abst) . . . . . 258  
 prevention of glomerulosclerosis, proteinuria (abst) . . . . . 281  
 prognosis and treatment of membranous nephropathy . . . . . 927  
 reduced 1,25(OH)<sub>2</sub>D<sub>3</sub>, calcium flux in (abst) . . . . . 165  
 remnant kidney, injury (abst) . . . . . 314  
 renal disease precedes (abst) . . . . . 259  
 renal function, withdrawal of treatment (abst) . . . . . 251  
 salt, Ca metabolism on calcium channel blockade  
 (abst) . . . . . 257  
 secondary, blood pressure after radical operation in  
 (abst) . . . . . 247  
 secondary, unilateral medullary adrenal hyperfunction  
 (abst) . . . . . 245  
 severe, in nephrotic syndrome . . . . . 188  
 spontaneously, renal dopamine receptors in (abst) . . . . . 245  
 trial of oral potassium (abst) . . . . . 259  
 unilateral parenchymatous kidney disease (abst) . . . . . 1259  
 varying protein diet, tubuloglomerular feedback . . . . . 520  
 Hypertonic cell volume regulation (abst) . . . . . 398  
 Hypertriglyceridemia (abst) . . . . . 327  
 Hypertrophy  
 biology of . . . . . 619  
 hyperplasia vs., angiotensin II epidermal growth (abst) . . . . . 318  
 Hypervolemia  
 plasma ANF (abst) . . . . . 395  
 Hypocalcemia  
 calcium carbonate controls in uremia . . . . . S-114  
 Hypokalemia, nephrocalcinosis (abst) . . . . . 183  
 Hyponatremia  
 clinical, role of vasopressin (abst) . . . . . 1258  
 correction of (abst) . . . . . 203  
 during forced diuresis for cancer chemotherapy (abst) . . . . . 191  
 encephalopathy (abst) . . . . . 177  
 hospital associated . . . . . 1237  
 prevention in Schwartz-Bartter Syndrome (abst) . . . . . 418  
 prognosis (abst) . . . . . 205  
 Hypoparathyroidism  
 Al induced osteomalacia (abst) . . . . . 218  
 Hypoperfusion  
 R2 chemoreceptor activation (abst) . . . . . 329  
 Hypophosphatemia, familial (abst) . . . . . 157  
 Hypoprothrombinemia, ARF (abst) . . . . . 177  
 Hyposic stress, lipid peroxidation(abst) . . . . . 303  
 Hypotension  
 atrial natriuretic peptide induced (abst) . . . . . 245  
 cardiopulmonary effects of cuprophane-activated  
 plasma . . . . . 799  
 cardiovascular response to hemofiltration . . . . . 901  
 lactic acidosis . . . . . 752  
 strategies to reduce in unstable HD patients (abst) . . . . . 224  
 Hypothyroidism  
 ESRD (abst) . . . . . 192  
 protects against free radical damage in ischemia . . . . . 1162  
 Hypotonic volume expansion (abst) . . . . . 420  
 Hypotonicity, K and CL (abst) . . . . . 406  
 Hypoxia  
 enhancement of erythropoietin production (abst) . . . . . 167  
 injury in the proximal tubule . . . . . 1021  
 isolated perfused kidney, 31P-NMR (abst) . . . . . 358  
 Hypoxic heart patients, NaHCO<sub>3</sub> (abst) . . . . . 180  
 Idiopathic nephrotic syndrome  
 (abst) . . . . . 189  
 asymptomatic renal vein thrombosis in (abst) . . . . . 207  
 IgA  
 antiglomerular, antibodies common in children (abst) . . . . . 282  
 Berger's disease in 50 renal biopsies (abst) . . . . . 191  
 Ery-M, PU, UE (abst) . . . . . 181  
 hereditary regionalization in (abst) . . . . . 209  
 immune complexes, polyethylene glycol assay (abst) . . . . . 278  
 in pulmonary diseases . . . . . 557  
 individual prognosis . . . . . 549  
 nephropathy in patients with liver cirrhosis (abst) . . . . . 1258  
 nephropathy, B cell hyperactivity . . . . . 718  
 scoring system (abst) . . . . . 205  
 synthesis by lymphocytes from patients, their relatives . . . . . 1229  
 IgG subclasses  
 idiopathic membranous glomerulonephritis (abst) . . . . . 287  
 Immune complex  
 dissolution by antibodies (abst) . . . . . 271  
 in children (abst) . . . . . 269  
 stimulate superoxide (abst) . . . . . 268  
 systemic lupus erythematosus (abst) . . . . . 276  
 Immune deposits in SLE patients (abst) . . . . . 295  
 Immunoblotting, 2D-SDS page (abst) . . . . . 1249  
 Immunodeficiency in CRF (abst) . . . . . 1257  
 Immunofluorescence, CMV antibody (abst) . . . . . 277  
 Immunohistochemical, amyloid (abst) . . . . . 274

- Immunological, non-mechanisms in progression of glomerulonephritis (abst) . . . . . 1172
- Immunoperoxidase  
  renin, kallikrein . . . . . 965  
  Mo Ab . . . . . 1043
- Immunoregulation  
  1,25(OH)2D3 (abst) . . . . . 264
- Indocin, peroral administration (abst) . . . . . 345
- Indomethacin  
  hyperfiltration (abst) . . . . . 942  
  in diabetes . . . . . 490  
  natriuresis (abst) . . . . . 336  
  renotropic effect of pooled sera (abst) . . . . . 339
- Indoxyl sulfate secretion (abst) . . . . . 317
- Infection  
  catheter (abst) . . . . . 232  
  urinary, reversal of ARF due to (abst) . . . . . 176
- Influenza vaccination in dialysis (abst) . . . . . 942
- Injury  
  glomerular epithelial cell, complement-induced (abst) . . . . . 272  
  glomerular, genetic factors of FSG . . . . . 789  
  glomerular, hypertension . . . . . 849  
  glomerular, PA nephrosis and oxygen free radicals . . . . . 478  
  hypertensive glomerular (abst) . . . . . 274  
  hypoxic in proximal tubule . . . . . 1021  
  immune, glomerular leukotriene (abst) . . . . . 339  
  immune, leukotriene B4 synthesis (abst) . . . . . 343  
  immunological response (abst) . . . . . 267  
  lipid alterations in LLC-PK1 cells, mercuric chloride . . . . . 530  
  postischemic ATP recovery (abst) . . . . . 299  
  proximal tubule, ischemia-reflow (abst) . . . . . 310  
  renal, radiocontrast decreased GFR (abst) . . . . . 300  
  tissue, characterization of mononuclear cell subsets . . . . . 1043  
  transport-dependent cell in S3 segment . . . . . 1033  
  vascular, c-sis mRNA (abst) . . . . . 272
- Inositol  
  phosphatidyl hydrolysis, vasopressin (abst) . . . . . 422  
  phospholipid phorbol myristate acetate (abst) . . . . . 348  
  phospholipid metabolism (abst) . . . . . 347  
  1,4,5-triphosphate releases  $\text{Ca}^{2+}$  . . . . . 695
- Insulin  
  ARF (abst) . . . . . 306  
  atrial natriuretic peptide increase (abst) . . . . . 348  
  degradation pathways (abst) . . . . . 355  
  dependent diabetes, indomethacin, hemodynamics . . . . . 490  
  effect of, role of pentose pathway (abst) . . . . . 161  
  luminal uptake and intracellular transport in tubules . . . . . 983  
  receptors, erythrocyte (abst) . . . . . 177  
  renal hemodynamics in isolated perfused kidney (abst) . . . . . 382  
  therapy, diabetic (abst) . . . . . 325  
  uremia, protein synthesis, degradation in skeletal muscle . . . . . 1136
- Intercalated cells  
  differ in CCT (abst) . . . . . 375  
  docpivalate (abst) . . . . . 372
- Interferon, type I, indomethacin (abst) . . . . . 276
- Interleukin  
  glucocorticoids inhibit transcription of (abst) . . . . . 431  
  1, allergic reactions during hemodialysis (abst) . . . . . 608  
  1, endothelium (abst) . . . . . 275  
  1, induction during HD (abst) . . . . . 219  
  1, mesangial cell (abst) . . . . . 282  
  1, induction during HD (abst) . . . . . 219  
  2, mitogenic to peripheral blood T cells (abst) . . . . . 286  
  2,1,25(OH)2D3 stimulates production (abst) . . . . . 160
- Interstitial  
  fluid volume, transcapillary colloid osmotic gradient . . . . . 895  
  fluid in cirrhotic, non-ascitic rat (abst) . . . . . 381  
  primary experimental nephritis, cyclophosphamide . . . . . 635  
  renal, cyclosporine (abst) . . . . . 303
- Intoxication, aluminum  
  hematopoiesis . . . . . S-45
- Intoxication, aluminum  
  in renal failure . . . . . S-70
- Intradialysis alimentation (abst) . . . . . 222
- Intrinsic sympathomimetic activity  
  renin response to beta blockade (abst) . . . . . 257
- Ion  
  ionic composition of body fluids . . . . . 120  
  23Na NMR spectroscopy of proximal tubule suspensions . . . . . 747  
  transport and glucose metabolism . . . . . 54
- Iron  
  suppression of PTH secretion by (abst) . . . . . 173
- Ischemia  
  catecholamines in (abst) . . . . . 310  
  cyclosporine nephrotoxicity (abst) . . . . . 304  
  cyclosporine nephrotoxicity by renal (abst) . . . . . 436  
  hypothyroidism protects against free radical damage . . . . . 1162  
  injury, enriched proximal tubules after (abst) . . . . . 353  
  injury, intracellular  $\text{Ca}^{++}$  (abst) . . . . . 300  
  lower ATP after insult (abst) . . . . . 310  
  malonaldehyde measurement following (abst) . . . . . 301  
  new Ca channel blocker following (abst) . . . . . 433  
  oxidant stress (abst) . . . . . 307  
  peripheral arterial, thromboxane synthetase (abst) . . . . . 777  
  post, ATP recovery (abst) . . . . . 315  
  proximal tubule injury (abst) . . . . . 310  
  renal acid-base metabolism after . . . . . 989  
  renal failure, protection against (abst) . . . . . 1254  
  therapeutic plasma levels of sulindac sulfide, hemorrhage . . . . . 484  
  verapamil and atriopeptin III (abst) . . . . . 943
- Isoenzymes in ESRD (abst) . . . . . 212
- Isolated perfused kidney  
  insulin effect on hemodynamics (abst) . . . . . 382  
  liver (abst) . . . . . 351  
  low molecular weight proteins (abst) . . . . . 354  
  remnant, load dependence of  $\text{H}_2\text{O}$ ,  $\text{HCO}_3$  reabsorption (abst) . . . . . 372  
  somatostatin 14, 28 metabolism in (abst) . . . . . 358
- Jaundice, renal dysfunction in . . . . . 598
- Juxtaglomerular epitheloid granular cell . . . . . 1234
- Kallikrein  
  cellular physiology of glandular . . . . . 953  
  renin, immunocytochemical localization in renal cortex . . . . . 965
- Kallikrein-kininogen-kinin system (abst) . . . . . 330
- Keratinocyte proliferation, D3 (abst) . . . . . 34A
- Ketoacidosis  
  acute reversal with  $\text{NaHCO}_3$  on plasma phosphorus and K (abst) . . . . . 374
- Kidney disease  
  eicosapentaenoic delays (abst) . . . . . 311
- Kinase  
  Ca/phospholipid dependent (abst) . . . . . 355  
  inhibition of aluminum . . . . . S-12
- Kinase-C regulation in tubules (abst) . . . . . 334



- Kinetic**  
atriopectin III (abst) ..... 340  
azlocillin's (abst) ..... 208  
during CAVH (abst) ..... 216  
formaldehyde (abst) ..... 213  
presteady state, Na<sup>+</sup>-H<sup>+</sup> exchange (abst) ..... 374  
stimulation Na<sup>+</sup>-H<sup>+</sup> (abst) ..... 370  
Kininase inhibitor in excretion (abst) ..... 348  
Kininogen  
urinary excretion, salt and water loading on (abst) ..... 349  
L-dopa in restless leg syndrome (abst) ..... 195  
L-platelet activating factor (abst) ..... 388  
Lactate stimulates K<sup>+</sup> (abst) ..... 350  
Lactate/acetate cocktail in HD (abst) ..... 220  
Lactic acidosis ..... 752  
Laminin  
antibodies to in preeclampsia ..... 1050  
heterogeneity (abst) ..... 284  
Lasix renography in utero (abst) ..... 208  
Lesion  
bone, natural course of dialysis osteomalacia ..... S-74  
cytomegalovirus glomerulopathy ..... 725  
dietary protein intake on albumin homeostasis ..... 572  
effects of antihypertensive treatment in hypertensive  
rats ..... 1011  
focal segmental glomerulosclerosis (abst) ..... 437  
focal segmental hyalinosis and sclerosis (abst) ..... 945  
genetic factors in focal segmental glomerulosclerosis ..... 789  
glomerulosclerosis, transgenic mouse model (abst) ..... 283  
immunosuppressive therapy of nephrotic syndrome  
(abst) ..... 1259  
interstitial, prognosis and treatment of membranous GN ..... 927  
polyarteritis nodosa (abst) ..... 272  
primary, tumor-associated, thrombotic  
microangiopathy (abst) ..... 280  
progressive, induced by lithium ..... 875  
renal, systemic lupus erythematosus study (abst) ..... 287  
Leukocyte  
and platelet-activating factor ..... 469  
C5a receptor, HD (abst) ..... 281  
esterase testing, CAPD (abst) ..... 234  
Leukopenia  
cardiopulmonary effects of cuprophane-activated  
plasma ..... 799  
Leukotriene  
administration, renal blood flow, cardiac output (abst) ..... 379  
B4 synthesis (abst) ..... 343  
C4, allograft reject (abst) ..... 332  
D4(LTD4) (abst) ..... 328  
immune injury (abst) ..... 339  
urine osmolality (abst) ..... 335  
Liganded platinum, respiration (abst) ..... 309  
Light chain deposition disease (abst) ..... 288  
Light chain nephropathy, aneurysm (abst) ..... 286  
Limulus amoebocyte lysate  
reactive material in chronic hemodialysis patients  
(abst) ..... 211  
Lipid  
alterations in LLC-PK1 cells exposed to mercuric chlo-  
ride ..... 530  
chemical mediators, PAF ..... 469  
peroxidation bradykinin induces increased (abst) ..... 333  
peroxidation ethane production a measure (abst) ..... 308  
peroxidation vitamin E in gentamicin induced (abst) ... 303  
peroxidation, hypoxic stress (abst) ..... 303  
phospho- and HgCl<sub>2</sub> injury ..... 496  
procoagulant activity in normal human urine ..... 591  
Lipoid nephrosis (abst) ..... 197  
Lipoprotein  
in glomerular disease with proteinuria ..... 1224  
receptor activity in epithelial cells ..... 1248  
Lithium  
chronic progressive renal lesions ..... 875  
effect on kidney function (abst) ..... 1255  
Liver disease  
renal, cardiovascular dysfunction ..... 598  
LLC PK1  
gap junctions in polarization process of (abst) ..... 404  
gluconeogenesis strain (abst) ..... 354  
lipid alterations in cells exposed to mercuric chloride .. 530  
Na-sugar cotransport (abst) ..... 418  
Na<sup>+</sup>/H<sup>+</sup> exchange system (abst) ..... 373  
sodium transport (abst) ..... 331  
LLCPK1-CL4  
cells, Na-H antiport activity in quiescent (abst) ..... 403  
Luminal bicarbonate concentration (abst) ..... 364  
Lupus erythematosus, MPCA (abst) ..... 270  
Lupus nephritis  
captopril improves (abst) ..... 277  
circulating immune complex (abst) ..... 295  
features of glomerular lesions (abst) ..... 196  
renal tubular function disturbances (abst) ..... 194  
transitions in renal histology (abst) ..... 293  
HD (abst) ..... 183  
Lupus SLE, antibodies (abst) ..... 283  
Luteinizing hormone, HD (abst) ..... 225  
Lymphocyte  
activation cascade, cyclosporine effect (abst) ..... 613  
ATP, hemodialysis (abst) ..... 327  
culture, soluble suppressor factor (abst) ..... 432  
IgA synthesis by, patients and their relatives ..... 1229  
in ICGN (abst) ..... 292  
peripheral, Cya influence (abst) ..... 1261  
role in experimental immune complex GN (abst) ..... 1249  
T4, T8 in rejection (abst) ..... 432  
Lymphokine  
nephrosis (abst) ..... 290  
release, T cells (abst) ..... 433  
Lysosomal enzymes, protein load (abst) ..... 357  
Lysine  
potassium depletion (abst) ..... 421  
Lysis in hematuria states (abst) ..... 183  
Macrophage procoagulant activity (abst) ..... 270  
Macula densa feedback (abst) ..... 389  
Magnesium hydroxide  
phosphate binder for maintenance hemodialysis (abst) ... 943  
K binder (abst) ..... 168  
Magnesium metabolism in SHR (abst) ..... 262  
Magnetic resonance imaging  
and ultrasound, in acquired renal cystic disease (abst) .. 196  
detection of renal allograft rejection (abst) ..... 434  
in diagnosis of renal vein thrombosis (abst) ..... 206  
in primary hyperoxaluria (abst) ..... 187  
loss of corticomedullary demarcation on (abst) ..... 429  
NMR & biochemistry ..... 131  
Maleic acid, glucose loading (abst) ..... 296  
Malignancies in CAPD patients (abst) ..... 231

- Malonaldehyde measure, ischemia (abst) ..... 301
- Mannitol and acute renal failure (abst) ..... 298
- Maxzide, reversible ARF (abst) ..... 198
- MDCK cells
- Na inhibits H-driven Na-H exchange (abst) ..... 397
- Measurement
- aluminum ..... S-24
- dialysate (abst) ..... 236
- Medulla
- H<sup>+</sup>-ATPase bovine, reconstitution (abst) ..... 366
- inner, ammonia concentration (abst) ..... 366
- Medullar collecting duct
- Cl/HCO<sub>3</sub> exchange, carbonic anhydrase inhibitor (abst) .. 379
- Medullary
- blood flow, ANF (abst) ..... 337
- dilatation, inner medullary collecting duct function (abst) ..... 394
- solute gradients, ANF (abst) ..... 414
- sponge kidney nephrolithiasis and hyperparathyroidism (abst) ..... 187
- thick ascending limb, transport inhibitor (abst) ..... 351
- washout, natriuresis (abst) ..... 407
- Membrane
- antibodies to laminin in preeclampsia ..... 1050
- apical and basolateral transporters, cell pH (abst) .... 362
- apical, cation conductance channels in (abst) ..... 393
- apical, basal cell, ionic conductances of (abst) ..... 396
- apical, conductance of amphiuma (abst) ..... 399
- apical, K transport in (abst) ..... 405
- apical, single sodium channel events in (abst) ..... 397
- BBM, BLM, differences in surface, inner core fluidity (abst) ..... 403
- biocompatibility ..... 225
- childhood membranoproliferative glomerulonephritis .. 1077
- cuprophane, cardiopulmonary effects of ..... 799
- depolarization, AII, AVP (abst) ..... 341
- optical measurement, DiS-C3-(5) response (abst) ..... 393
- peritoneal dialysis (abst) ..... 236
- podocyte plasma, internal heterogeneity (abst) ..... 1248
- properties of fused renal epithelial cells (abst) ..... 1251
- renal, basolateral, Na-Ca exchange (abst) ..... 425
- Membranoproliferative glomerulonephritis
- adult idiopathic nephrotic syndrome (abst) ..... 207
- benefit of cyclophosphamide therapy in (abst) ..... 192
- childhood, an approach to management ..... 1077
- Membranous glomerulopathy
- glomerular sieving defect in rat (abst) ..... 390
- pathophysiology of (abst) ..... 323
- Membranous nephropathy
- C6 depletion diminishes proteinuria (abst) ..... 287
- Mercuric chloride
- autoimmune glomerulonephritis (abst) ..... 608
- lipid alterations in LLC-PK1 cells ..... 530
- phospholipids ..... 496
- Mercury
- basolateral membrane (abst) ..... 416
- renal injury (abst) ..... 199
- Mesangial
- cell behavior control (abst) ..... 275
- cell damage, complement (abst) ..... 296
- expansion, glomerular filtration surface in diabetes ... 889
- expansion, polyamine (abst) ..... 267
- in vitro, cell culture and characterization (abst) ..... 944
- prostanoid, Il-1 (abst) ..... 282
- secrete growth factor-like molecule (abst) ..... 263
- Mesangium, renal, IgA nephropathy ..... 1229
- Metabolic alkalemia, acidification(abst) ..... 363
- Metabolic function
- and transport in cultured renal tubule cell ..... 46
- Metabolism
- adaptations of the nephron in renal disease ..... 80
- deformylase activity, renal, in drugs and xenobiotics (abst) ..... 361
- glucose in renal tubular function ..... 54
- glutamine, lactate, alanine, oxygen; fluorocitrate (abst) . 353
- iron, interference by aluminum ..... S-45
- lactic acidosis ..... 752
- metabolic fuels along the nephron ..... 41
- mitochondrial volumes and hepatic GLN homeostasis (abst) ..... 370
- nitrogen, energy intake in nondialyzed patients CRF ... 734
- oxidative in hypertensive rats (abst) ..... 242
- phospholipid, biology of renal hypertrophy ..... 619
- protein loading and pH (abst) ..... 361
- protein loading on renal (abst) ..... 361
- regulation of glutamine in dog kidney ..... 68
- renal calcitonin (abst) ..... 359
- sites of action of vitamin D in the kidney ..... 98
- 2-amino-4-(5-nitro-2-furyl) thiazole in cancer (abst) ... 360
- Metabolites, prostaglandins ..... 108
- Metals, heavy, phospholipids ..... 496
- Methionine oxidation and PTH (abst) ..... 169
- Methotrexate overdose (abst) ..... 216
- MHC product expression (abst) ..... 276
- Microcytic anemia, non-aluminum in ..... S-120
- Microprobe techniques, x-ray ..... 682
- Mineral acid feeding, systemic pH ..... 667
- Mineralization
- abnormalities, bone aluminum intoxication ..... S-70
- aluminum inhibits ..... S-32
- bone development, Al ..... 1038
- Mineralocorticoid
- adrenoceptors (abst) ..... 1258
- escape, ANP (abst) ..... 329
- Mitochondrial
- electron transport (abst) ..... 305
- function, HgCl<sub>2</sub> ..... 496
- store site, non- in rat ..... 695
- Model, isolated perfused kidney (abst) ..... 351
- Molecule, class I, T lymphocytes (abst) ..... 270
- Monoclonal antibodies
- BB5 on PTH (abst) ..... 156
- bovine H<sup>+</sup> ATPase (abst) ..... 369
- culture of pure population of proximal tubules (abst) ... 360
- in diagnosis ..... 142
- production for distal tubule cell types (abst) ..... 360
- used for reaoimmunoassay to bradykinin (abst) ..... 342
- in diagnosis ..... 142
- Monocytosis, eosinophilia (abst) ..... 231
- Mononuclear cell
- markers, rejection ..... 708
- reduced IGA-secreting, after tonsillectomy (abst) ..... 290
- subsets ..... 1043
- Morbidity in renal failure (abst) ..... 202
- Mortality risk on maintenance HD (abst) ..... 228
- mRNA, regulation by 1,25(OH)<sub>2</sub>D<sub>3</sub> (abst) ..... 172
- Multiple myeloma, plasmapheresis (abst) ..... 199
- Murine
- autoimmunity, Ia (abst) ..... 289
- monoclonal antibodies, tumor derived (abst) ..... 284

- polycystic kidney disease (abst)..... 314  
 Muscle, skeletal, protein synthesis ..... 1136  
 Musculoskeletal, Al in bone disease ..... S-80  
 Muzlimine, loop diuretic (abst) ..... 1255  
 Myeloperoxidase H<sub>2</sub>O<sub>2</sub> halide system(abst)..... 271  
 Myocardial  
   funtion, hemodialysis (abst)..... 212  
   infarction in ESRD (abst)..... 185  
 Myoglobinuric acute renal failure  
   theophylline-induced protection in (abst) ..... 299  
 N-acetyl-beta-glucosaminidase  
   decrease after antihypertensive therapy (abst) ..... 258  
 Nagogastric tube and CPD, infants (abst)..... 230  
 Naloxone, water immersion (abst)..... 1259  
 Natriuresis  
   albumin infusion not induce (abst)..... 392  
   anti-diuretic induced (abst)..... 422  
   atrial extracts in rats (abst) ..... 248  
   atrial natriuretic peptide on hydraulic pressures (abst) .. 382  
   atrial peptide, mechanisms (abst)..... 383  
   hormone marker (abst)..... 240  
   indomethacin on, by atriopeptin III (abst)..... 336  
   medullary washout (abst)..... 407  
   prostaglandins not mediate pressure (abst)..... 347  
   proteinuria, aldose reductase inhibition (abst)..... 391  
   sodium diclofenac inhibits effect (abst) ..... 328  
   verapamil induced in CVAL dogs (abst) ..... 382  
 Neonate, chloride deficiency (abst)..... 186  
 Nephrectomy  
   biology of renal hypertrophy ..... 619  
   low protein, phosphate diet inhibit proteinuria (abst) ... 326  
   potassium depletion mediates extrarenal adaptation  
     (abst) ..... 408  
   unilateral, CyA (abst)..... 426  
   long-term renal response to high protein in dogs..... 511  
   5/6, clofibrac acid (abst) ..... 324  
 Nephritis  
   auto-immune, anti-GBM antibodies (abst)..... 266  
   Henoch-schonlein IgG, IgA antibodies common (abst) .. 282  
   HgCl<sub>2</sub> induced, methylprednisolone,  
     bycophosphamide (abst) ..... 775  
   interstitial, B cell in aTBM (abst) ..... 270  
   interstitial T cell factor on development (abst) ..... 286  
   lupus, renal histology with outcome in children ..... 1066  
   nephrotoxic, PAF (abst)..... 282  
   nephrotoxic serum, antiotensin 2 receptors (abst) ..... 293  
   nephrotoxic serum, stress (abst) ..... 266  
   primary experimental interstitial, cyclophosphamide ... 635  
   spontaneous interstitial, suppression T cells (abst)..... 280  
   streptococcus mutans infusion (abst)..... 264  
   transitions in renal histology (abst) ..... 293  
   1-J+ suppressor T cells (abst) ..... 284  
 Nephrocalcinosis, hypokalemia (abst)..... 183  
 Nephrolithiasis  
   idiopathic calcium, membrane defect a factor in (abst) . 609  
   tubulopathy..... 563  
 Nephrologist urinalysis survey (abst) ..... 184  
 Nephron  
   juxtamedullary ANP on whole kidney and (abst) ..... 405  
   kallikrein-kinin system ..... 120  
   metabolic adaptations of in renal disease ..... 80  
   metabolism and sites of action of vitamin D in the kid-  
     ney ..... 98  
   prostaglandins and other arachidonic acid metabolites .. 108  
   remnant circulation, autoregulation (abst)..... 384  
 Nephropathy  
   adriamycin-induced, progressive glomerular disease ... 502  
   alcohol-associated, complex tubular dysfunction (abst) . 609  
   early, immunological features in diabetes and (abst) ... 611  
   experimental membranous, antigen and urinary protein  
     (abst)..... 292  
   gold, detection of autoantibodies to renal tubular anti-  
     gens..... 539  
   hepatic, pathogenesis of (abst)..... 285  
   idiopathic IGA after tonsillectomy (abst) ..... 290  
   IgA, C3 deposition (abst)..... 274  
   IgA, individual prognosis ..... 549  
   light chain, transplantation (abst)..... 943  
   lithium induced interstitial ..... 875  
   membranous, prognosis and treatment ..... 927  
 Nephrosis  
   aminonucleoside ..... 478  
   aminonucleoside heparan-sulfate proteoglycans in  
     (abst)..... 281  
   dietary protein intake ..... 572  
   lymphokine, SIRS (abst) ..... 290  
   relapse (abst) ..... 193  
 Nephrotic syndrome  
   adult-onset, long-term follow-up ..... 1215  
   aldosterone in Na retention (abst) ..... 203  
   antiotensin converting enzyme activity increased (abst). 302  
   children, cyclosporine A remission (abst) ..... 206  
   colloid volume expansion on glomerular barrier ..... 916  
   CyA inhibits trypanosomiasis-induced (abst)..... 1256  
   focal segmental hyalinosis and sclerosis lesions (abst) .. 945  
   focal, segmental glomerular sclerosis, AIDS (abst)..... 288  
   idiopathic, food allergy (abst) ..... 776  
   idiopathic, molecular basis for in children (abst) ..... 189  
   immunosuppressive therapy, retrospective of 55 adults  
     (abst) ..... 1258  
   lowered tissue-fluid oncotic pressure (abst)..... 194  
   membranous nephropathy, prognosis and treatment. ... 927  
   membranous nephropathy, prognosis and treatment. ... 927  
   remission induced by ultrafiltration ..... 776  
   severe hypertension in (abst)..... 188  
   transferrin rectptors on lymphocytes in children (abst) . 294  
 Nephrotoxic serum nephritis (abst)..... 266  
 Nephrotoxicity  
   cyclosporine enhances endotoxin (abst) ..... 431  
   cyclosporine, by ischemia (abst) ..... 436  
   cyclosporine, immunohistologic labeling of biopsy  
     (abst)..... 432  
   gentamicin (abst) ..... 297  
   gentamicin, glomerular prostaglandin production in  
     (abst)..... 298  
   gentamicin, PTH in PTX rats (abst) ..... 301  
   lithium lesions..... 875  
   renal cortical subcellular membrane phospholipids,  
     HgCl<sub>2</sub> ..... 496  
   vasoconstriction in CyA transplant recipients (abst). ... 428  
   cyclosporine A (abst) ..... 1216  
   stimulation, gluconeogenesis (abst) ..... 349  
 Nerves  
   renal in hypertensive (abst) ..... 256  
   renal response to Na (abst) ..... 253  
   stimulation, gluconeogenesis (abst) ..... 349  
 Neurogenic mechanism, hypertensive(abst) ..... 256  
 Neurological disorder in dialysis ..... S-104  
 Neutropenia, minimal, C102 (abst) ..... 221



- Neutrophils  
 PMA-stimulated (abst) ..... 291  
 stimulated, cAMP content in glomeruli (abst) ..... 349
- Newborn  
 ARF, continuous arterio-venous hemofiltration ..... 908  
 pseudohypoaldosteronism (abst) ..... 943
- Newcastle bone disease  
 aluminum-induced dialysis osteodystrophy ..... S-58
- Nicotinamide inhibits K transport (abst) ..... 161
- Nifedipine  
 effect on carbohydrate metabolism (abst) ..... 1257  
 therapy, renal failure (abst) ..... 778
- Nipride in SHR (abst) ..... 243
- Nitrogen  
 glutamine, in kidney (abst) ..... 350
- NMR spectroscopy  
 of proximal tubule suspensions ..... 747
- Nonglomerular renal diseases (abst) ..... 180
- Noninvasive study of the kidney  
 P NMR spectroscopy ..... 137
- Nordihydroguaiaretic acid, cysts in rat ..... 1116
- Norepinephrine  
 ARF (abst) ..... 306  
 pressor response (abst) ..... 261  
 oxygen consumption, Na-K ATPase activity (abst) ..... 391  
 volume absorption in PCT (abst) ..... 394
- Nuclear magnetic resonance, biochemistry ..... 131
- Nucleosides, transport (abst) ..... 1253
- Nucleotide  
 adenine, after anoxia (abst) ..... 357  
 exogenous, ATP (abst) ..... 356
- Nural regulation alkali excretion (abst) ..... 365
- Nutrition  
 low protein-essential amino acid-keto acid diet ..... 995
- Nypernephroma, ESRD (abst) ..... 433
- O-(beta-hydroxyethyl) rutoside (abst) ..... 300
- Obstruction, ureteral, acidification ..... 1167
- Occluded arteriovenous access  
 thrombolysis using i.v. urokinase (abst) ..... 223
- Oncotic pressure  
 lowered tissue-fluid, protects blood volume in NS  
 (abst) ..... 194
- Optical measurement membrane (abst) ..... 393
- Ornithine decarboxylase activity (abst) ..... 357
- Osmotic gradient, H<sub>2</sub>O in PCT (abst) ..... 412
- Osteitis fibrosa, dialysis osteomalacia ..... S-74
- Osteodystrophy  
 aluminum and genesis of (abst) ..... 169  
 aluminum-induced dialysis, Newcastle bone disease... S-58  
 changes in bone histology after desferrioxamine treatment ..... S-108  
 disability and bone Al in hemodialysis patients (abst) .. 168  
 encephalopathy in renal failure, desferrioxamine .... S-100  
 parathyroid hormone and aluminum levels ..... S-41  
 phosphate binding gels balance Al toxicity ..... 1131  
 renal in CAPD (abst) ..... 237  
 unresponsiveness of bone to PTH in aluminum-related .. S-49  
 99mTc-methylene diphosphonate bone scan ..... 1058  
 renal in CAPD (abst) ..... 237
- Osteomalacia  
 aluminum effect on bone and cell localization ..... S-37  
 Al-induced (abst) ..... 218  
 aluminum-induced, inhibition of apatite formation ... S-17  
 diagnosis of aluminum bone disease ..... S-96  
 PTH not prevent Al induced (abst) ..... 168
- Ouabain, vanadate (abst) ..... 330
- Oxalate  
 assay by GC/MS isotope (abst) ..... 202  
 in CRF (abst) ..... 321  
 mechanism of transport by rat ileum (abst) ..... 161
- Oxidant stress, ischemia (abst) ..... 307
- Oxidative stress, PTS (abst) ..... 307
- Oxygen  
 consumption of ouabain, amphotericin B, nystatin  
 (abst) ..... 611  
 consumption, sodium transport & ATP ..... 3  
 deprivation, ATP levels (abst) ..... 296  
 free radical in aminonucleoside nephrosis ..... 478  
 glutathione depleters, effect on proximal tubules ..... 858
- PAF-acether, renal actions (abst) ..... 342
- PAH reabsorption, transport (abst) ..... 371
- Pan-electrolyte depletion (abst) ..... 187
- Pancreatitis absence in ESRD (abst) ..... 217
- Papilla  
 and glomeruli, sulfidopeptide leukotriene (abst) ..... 346
- Papillary cells, sorbitol (abst) ..... 412
- Papillary collecting duct, x-ray ..... 675
- Paraaminohippurate transport (abst) ..... 424
- Paraproteinemia (abst) ..... 174
- Parathyroid glands, transplant (abst) ..... 170
- Parathyroid hormone  
 activated calcium conductive pathway in brush border  
 (abst) ..... 166  
 age and (abst) ..... 175  
 aluminum bone disease ..... S-87  
 aluminum induced bone disease ..... S-32  
 and 1,25(OH)<sub>2</sub>D<sub>3</sub> maintain activity of bone cells (abst) . 165  
 assay, amino-terminal vs. carboxy-terminal ..... 239  
 bicarbonate absorption in urinary acidification (abst) ... 363  
 Ca<sup>2+</sup> transport by ATPase of endoplasmic reticulum  
 (abst) ..... 421  
 clinical evidence on interactions with 1,25(OH)<sub>2</sub>D<sub>3</sub> .... 202  
 compensatory renal growth by Ca, 1,25(OH)<sub>2</sub>D<sub>3</sub> ..... 1124  
 cytosolic calcium effect of (abst) ..... 175  
 dependent phosphorylation of proteins in tubules (abst) .. 167  
 dialysis osteomalacia ..... S-74  
 effect of aluminum on secretion ..... S-41  
 effect of aluminum on tissue incubation medium ..... 924  
 effect of monoclonal antibody BB5 on (abst) ..... 156  
 effects on water flow in toad bladder ..... 170  
 enhances stimulatory effect of Ca<sup>+</sup> on aldosterone  
 (abst) ..... 168  
 gentamicin nephrotoxicity, PTH in PTX (abst) ..... 301  
 glucagon, effect on juxtamedullary nephrons ..... 807  
 high dialysate Ca and 1,25(OH)<sub>2</sub>D<sub>3</sub> effect (abst) ..... 231  
 induced dephosphorylation of protein (abst) ..... 171  
 modulates V<sub>max</sub>, pH of na/h antiporter (abst) ..... 372  
 Na<sup>+</sup>-Ca<sup>+</sup> exchange (abst) ..... 171  
 oxidation of specific methionine residues of (abst) .... 169  
 response of plasma 1,25(OH)<sub>2</sub>D<sub>3</sub> on (abst) ..... 158  
 role in hypercalcemia and hypertension (abst) ..... 248  
 secretion and U<sub>Ca</sub> during sequential changes of Ca  
 (abst) ..... 172  
 skeletal resistance to, in uremia (abst) ..... 319  
 stimulates cellular calcium absorption (abst) ..... 159  
 suppression by WR-2721 ..... 174  
 unresponsiveness of bone to, in Al-related osteodystro-  
 phy ..... S-49

- Parathyroidectomy  
 effects on renal PO<sub>4</sub> handling (abst) ..... 161  
 fall in 1,25(OH)<sub>2</sub>D<sub>3</sub> and bone GLA (abst) ..... 186  
 Parathyroidectomy, PTH, Ca (abst) ..... 322  
 Parenchymatous kidney disease (abst) ..... 1259  
 Pars recta, rabbit  
 arachidonate acid epoxigenase activity (abst) ..... 356  
 Pathologic scoring system, IGAN (abst) ..... 205  
 Pentose pathway, role (abst) ..... 161  
 Peptide  
 and amine hormones, Ca and cyclic AMP ..... 90  
 atriopeptin II effect on arterioles (abst) ..... 333  
 cellular physiology of glandular kallikrein ..... 953  
 Perenteral solution (abst) ..... 369  
 Peripheral blood mononuclear cells, IgA ..... 718  
 Peritoneal  
 dialysis schedule (abst) ..... 233  
 mass transfer, effect of dialysate volume (abst) ..... 235  
 transport, model (abst) ..... 234  
 Peritoneovenous shunt in HRS (abst) ..... 196  
 Peritoneum, dextran transfer (abst) ..... 232  
 Peritonitis  
 increased fibronectin concentration during, CAPD  
 (abst) ..... 232  
 reduction of CAPD, by UV-XD system (abst) ..... 240  
 risk of intermittent dialysis in hospital (abst) ..... 238  
 sclerosing encapsulating induced by chlorhexidine  
 (abst) ..... 234  
 treatment with vancomycin in CAPD (abst) ..... 229  
 Permeability  
 brush border membrane, age related changes (abst) ..... 414  
 cholera toxin increases water permeability (abst) ..... 417  
 inner medullary collecting duct, surfact epithelium  
 (abst) ..... 418  
 regulation of water in ADH and cAMP treated bladder  
 (abst) ..... 417  
 tubular water, adrenal steroids affect (abst) ..... 417  
 Peroral administration indocin (abst) ..... 345  
 Pertussis toxin  
 AII, PGE<sub>2</sub> (abst) ..... 344  
 in renin (abst) ..... 342  
 PGE<sub>2</sub>, hydrogen peroxide (abst) ..... 291  
 pH  
 acetazolamide increases (abst) ..... 366  
 chronic mineral acid feeding, systemic ..... 667  
 in MDCK cells, kinetics of Na-H antiporter (abst) ..... 376  
 luminal, peritubular, on citrate reabsorption (abst) ..... 413  
 mitochondria-rich cells, turtle bladder regulate (abst) ..... 378  
 radial gradient in cortical collecting duct lumen (abst) ..... 377  
 Pharmacokinetics in CAPD (abst) ..... 236  
 Phlebotomies, effect (abst) ..... 776  
 Phorbol ester  
 alkalization (abst) ..... 372  
 fluid and phosphate fluxes in tubules (abst) ..... 411  
 hyperosmolarity, cation fluxes in mTALH (abst) ..... 395  
 stimulate Na<sup>+</sup>/H<sup>+</sup> exchange in renal brush border  
 (abst) ..... 408  
 Phorbol myristate acetate  
 (abst) ..... 338  
 InsPL (abst) ..... 348  
 Phosphate  
 alkalosis on transport by renal proximal tubule (abst) ..... 163  
 binding compound, non-aluminum ..... S-120  
 binding gels, balance K adsorption and Al toxicity ..... 1131  
 cytosolic, metabolism in familial hypophosphatemia  
 (abst) ..... 157  
 depletion arrests progression of CRF independent of  
 protein ..... 658  
 depletion, proteinuria of diabetes (abst) ..... 313  
 diet, response of senescent rats to (abst) ..... 162  
 dietary intake on serum vitamin D metabolites (abst) ..... 609  
 epithelial inorganic transport (abst) ..... 172  
 groups and anionic sites in glomerulus (abst) ..... 285  
 impairment of reabsorption by chronic hypercalcemia  
 (abst) ..... 163  
 Mg(OH)<sub>2</sub> binder (abst) ..... 168  
 Na-dependent in LLC-PK1 cells (abst) ..... 167  
 NMR spectroscopy ..... 131  
 phosphonocarboxylic acids inhibit transport (abst) ..... 172  
 prevention of secondary hyperparathyroidism by (abst) ..... 164  
 regulation of intestinal absorption, vitamin D (abst) ..... 163  
 transport, effects of Pi (abst) ..... 171  
 transport inhibition (abst) ..... 164  
 uptake by luminal membrane (abst) ..... 155  
 Phosphatidylcholine transfer  
 (abst) ..... 162  
 stimulation by 1,25(OH)<sub>2</sub>D<sub>3</sub> involves brush border  
 (abst) ..... 174  
 Phosphatidylinositol, gentamicin (abst) ..... 308  
 Phosphoinositide metabolism (abst) ..... 353  
 Phospholipase A<sub>2</sub> in uremia (abst) ..... 316  
 Phospholipase D, urokinase (abst) ..... 344  
 Phospholipase, exogenous, PTS (abst) ..... 307  
 Phospholipid, BBM, BLM in SHR (abst) ..... 252  
 Phospholipidosis, gentamicin (abst) ..... 311  
 Phosphonoformic Acid on Pi (abst) ..... 174  
 Phosphoramidon, effect in renal (abst) ..... 348  
 Phosphorus  
 compensatory renal growth, modulation ..... 1124  
 synthesis of 1,25(OH)<sub>2</sub>D<sub>3</sub> in proximal tubules (abst) ..... 162  
 Phosphorylation  
 IGF I stimulated, renal basolateral membranes (abst) ..... 354  
 Pituitary-renotropin, renal growth(abst) ..... 341  
 Plasma  
 chronic sodium homeostasis and ANF ..... 1004  
 therapeutic levels of sulindac sulfide during hemorrhage ..... 484  
 during hemodialysis (abst) ..... 203  
 Plasma arginine vasopressin  
 (abst) ..... 346  
 hospital-associated hyponatremia ..... 1237  
 modulation by cardiac function ..... 1188  
 Plasma chromagranin A in RF (abst) ..... 198  
 Plasma kallikrein ..... 120  
 Plasma polypeptides, hypertension (abst) ..... 260  
 Plasma renin  
 dietary NaCl (abst) ..... 349  
 Plasma transferrin after DFO (abst) ..... 225  
 Plasma vasopressin  
 humoral control of water and electrolyte excretion ..... 1152  
 Plasmapheresis  
 multiple myeloma (abst) ..... 199  
 treatment of renal graft rejection (abst) ..... 613  
 Plasminogen activator  
 polyunsaturated fatty acids decrease EC production  
 (abst) ..... 279  
 Plasmodium Yoelii, malarial GLN (abst) ..... 280  
 Plasticizer DI-2-(ethylhexyl) (abst) ..... 214  
 Platelet activating factor, NTN (abst) ..... 282, 469  
 Platelet derived growth factor (abst) ..... 263

- Pneumonia  
 Goodpasture's syndroms as post-mycoplasma (abst) . . 1256  
 podocyte plasma membrane (abst) . . . . . 1248  
 Pokeweed mitogen, IgA synthesis . . . . . 718  
 Polarized cells  
   regulation of growth and function . . . . . 46  
 Polyamine, mesangial expansion (abst) . . . . . 267  
 Polyanion, glomerular in PAN (abst) . . . . . 276  
 Polyarteritis Nodosa, lesions (abst) . . . . . 272  
 Polyclonal immune response (abst) . . . . . 268  
 Polycystic kidney disease  
   tubular changes during development (abst) . . . . . 320  
   adult (abst) . . . . . 181  
   autosomal dominant, epithelial hyperplastic (abst) . . . . . 276  
   changes in tubular basement membrane (abst) . . . . . 268  
   reduce (abst) . . . . . 179  
   steroid metabolism (abst) . . . . . 271  
   transplantation (abst) . . . . . 437  
   trimethoprim sulfamethoxazole in cyst fluid (abst) . . . . . 185  
   ultrastructure of cyst derived epithelium (abst) . . . . . 323  
 Polyelectrolyte, gelifundol (abst) . . . . . 230  
 Polyethylene glycol assay, IgA (abst) . . . . . 278  
 Polymorphonuclear neutrophils  
   dialysis membranes, electrical charge (abst) . . . . . 609  
 Polypeptide, 60kDa duplet (abst) . . . . . 279  
 Porphyrin metabolism and Al (abst) . . . . . 211  
 Positive end expiratory pressure (abst) . . . . . 415  
 Poststreptococcal  
   glomerulonephritis in children (abst) . . . . . 178  
 Potassium  
   acidosis (abst) . . . . . 363  
   ATPase, distribution and function of classes of . . . . . 21  
   bicarbonate on Na-K-ATPase in CCD (abst) . . . . . 395  
   chronic loading in man (abst) . . . . . 1251  
   conductance of cells, early distal vonvoluted (abst) . . . . . 409  
   depletion during chronic metabolic acidosis (abst) . . . . . 374  
   depletion effect on brain buffering (abst) . . . . . 362  
   depletion mediates extrarenal adaptation (abst) . . . . . 408  
   depletion on HCO<sub>3</sub> transport (abst) . . . . . 368  
   depletion, antihypertensive effect (abst) . . . . . 255  
   depletion, lysine (abst) . . . . . 421  
   diet on transport of CCD of adrenalectomized rabbit  
     (abst) . . . . . 403  
   diet reduces brain infarcts (abst) . . . . . 250  
   efflux, furosemide-sensitive (abst) . . . . . 396  
   electrolyte concentrations of renal cortex (abst) . . . . . 1251  
   ESRD (abst) . . . . . 324  
   K-pump, reabsorptive in K depleted rat (abst) . . . . . 400  
   lactate stimulates (abst) . . . . . 350  
   regulation of, conductance in MDCK cells (abst) . . . . . 1251  
   test of in hypertension (abst) . . . . . 259  
   transport in apical membrane vesicles (abst) . . . . . 405  
 Precipitation, Ca and K, Al effect . . . . . S-20  
 Prediction of outcome in ARF (abst) . . . . . 184  
 Preeclampsia, antibodies to laminin . . . . . 1050  
 Pregnancy  
   antibodies to laminin in preeclampsia . . . . . 1050  
 Pressor response, glucocorticoids (abst) . . . . . 246  
 Primary nephrotic syndrome  
   biopsy in 65 teenagers (abst) . . . . . 284  
 Prioxicam, diabetics . . . . . 611  
 Procoagulant activity  
   in urine . . . . . 591  
   rabbits (abst) . . . . . 295  
 Prognostic factors in cirrhosis (abst) . . . . . 184  
 Progressive renal disease  
   anti-hypertensive drugs (abst) . . . . . 314  
 Prolactin  
   excess causes hypercalcuria (abst) . . . . . 156  
   levels in CRF (abst) . . . . . 322  
 Prostacyclin synthesis (abst) . . . . . 260  
 Prostaglandin  
   ADH, sodium excretion in IEPK (abst) . . . . . 401  
   alpha 2 adrenoceptors, cAMP (abst) . . . . . 346  
   and other arachidonic acid metabolites in the kidney . . . . . 108  
   and thromboxane production, protein (abst) . . . . . 336  
   AII, AVP, bradykinin, meclofenamate on, cAMP sys-  
     tems (abst) . . . . . 341  
   AII, AVP, bradykinin, meclofenamate on, cAMP sys-  
     tems (abst) . . . . . 341  
   dependent, R2 chemoreceptor activation (abst) . . . . . 329  
   E2, furosemide (abst) . . . . . 337  
   glomerular, gentamicin nephrotoxicity (abst) . . . . . 298  
   glomerular vasodilatory, diet induced hyperfiltration  
     (abst) . . . . . 343  
   hexose monophosphate shunt activity (abst) . . . . . 338  
   histidine (abst) . . . . . 331  
   hyperfiltration of early diabetes (abst) . . . . . 332  
   in cirrhotic rats (abst) . . . . . 343  
   in nephrectomy (abst) . . . . . 329  
   increased urinary excretion of, during antidiuresis,  
     DDAVP . . . . . 1110  
   isolated renal afferent arteriole, production (abst) . . . . . 385  
   mediated loss of proteins during peritonitis in CAPD . . . . . 584  
   nerve-induced glomerular dynamics (abst) . . . . . 334  
   not mediate pressure natriuresis (abst) . . . . . 347  
   pregnancy, urinary excretion during hypertension  
     (abst) . . . . . 777  
   regulation of renal cellular cAMP levels by . . . . . 703  
   regulatory in remnant glomerulus (abst) . . . . . 341  
   renal blood flow in ARF (abst) . . . . . 342  
   renal cortical mitochondrial ammoniogenesis (abst) . . . . . 355  
   renin release in uninephrectomy (abst) . . . . . 381  
   renovascular resistance determinant of response (abst) . . . . . 337  
   synthesis on renal sodium handling (abst) . . . . . 405  
   synthesis in renal papillae (abst) . . . . . 345  
 Prostanoid production GEC (abst) . . . . . 277  
 Prostate and pituitary, kallikrein . . . . . 953  
 Protease  
   cytotoxic factor (abst) . . . . . 283  
   free renin preparation (abst) . . . . . 343  
   NGN (abst) . . . . . 275  
 Protein  
   aldosterone, short circuit current and conductance  
     (abst) . . . . . 408  
   aluminum sites in . . . . . S-12  
   angiotensin II, BP and vascular reactivity (abst) . . . . . 383  
   atrial natriuretic factor during change in (abst) . . . . . 384  
   band 3 anion exchange in rabbit (abst) . . . . . 376  
   biology of renal hypertrophy . . . . . 619  
   binding, indoxyl sulfate secretion (abst) . . . . . 317  
   binding of cefamandole (abst) . . . . . 239  
   bolus, effect on GFR (abst) . . . . . 339  
   chronic renal insufficiency (abst) . . . . . 318  
   dietary intake on albumin homeostasis in nephrotics . . . . . 572  
   dietary, gentamicin nephrotoxicity (abst) . . . . . 297  
   dietary, long-term response in dogs with . . . . . 75  
   nephrectomy . . . . . 511  
   effect of loading in remnant rat kidney (abst) . . . . . 324  
   effect on normal kidney (abst) . . . . . 297



- experimental diabetes mellitus (abst) . . . . . 289  
 fenoldopam (abst) . . . . . 313  
 filtration fraction among superficial nephrons . . . . . 814  
 GFR, albumin, renal growth after increased (abst) . . . . . 321  
 glomerular function in human renal disease (abst) . . . . . 325  
 glomerular injury in antihypertensive therapy (abst) . . . . . 319  
 guanine nucleotide regulatory in TAL (abst) . . . . . 333  
 influence of charge, cathepsin activity (abst) . . . . . 293  
 inhibitory nucleotide regulatory mediates ADH (abst) . . . . . 423  
 interactions of aluminum with cofactors, enzymes and. S-12  
 load on lysosomal enzymes in proximal tubule (abst) . . . . . 357  
 loading, glucose control (abst) . . . . . 196  
 loading, on renal metabolism (abst) . . . . . 361  
 low, essential amino acid diet, risk and benefit . . . . . 995  
 low molecular weight in isolated perfused kidney (abst) . . . . . 354  
 phosphate depletion arrests progression of CRF with-  
 out . . . . . 658  
 phosphorylation, angiotensin II (abst) . . . . . 329  
 prostaglandin-mediated loss during peritonitis . . . . . 584  
 renal amyloid lambda 2 light chain subgroup (abst) . . . . . 288  
 synthesis and degradation in skeletal muscle, uremic  
 rats . . . . . 1136  
 Tamm-Horsfall, antibodies for . . . . . 971  
 tubuloglomerular feedback, glomerular morphology . . . . . 520  
 uninephrectomy and, volume reabsorption (abst) . . . . . 320  
 urinary, antigen in experimental membranous  
 nephropathy(abst) . . . . . 292  
**Proteinuria**  
 adriamycin-induced, cyclosporine exacerbates (abst) . . . . . 434  
 adult onset, minimal change nephrotic syndrome . . . . . 1215  
 angiotensin II induced (abst) . . . . . 270  
 childhood membranoproliferative glomerulonephritis . . . . . 1077  
 colloid volume expansion on glomerular barrier . . . . . 916  
 converting enzyme inhibition prevents (abst) . . . . . 265  
 C6 depletion diminishes in membranous nephropathy  
 (abst) . . . . . 287  
 glomerular epithelial cell,protein overload (abst) . . . . . 290  
 glomerular, effect of dietary protein on albumin  
 homeostasis . . . . . 572  
 in diabetic influenced by metabolic control and BP  
 (abst) . . . . . 189  
 induced by aminonucleoside of puromycin . . . . . 478  
 low protein, phosphate inhibit (abst) . . . . . 326  
 membranous glomerulopathy (abst) . . . . . 323  
 natriuresis, aldose reductase inhibition (abst) . . . . . 391  
 nephrotic plasma increases (abst) . . . . . 295  
 prognosis and treatment of membranous nephropathy . . . . . 927  
 protein restriction in diabetic nephropathy (abst) . . . . . 209  
 serum and urinary high density lipoproteins . . . . . 1224  
 thromboxane synthesis inhibition (abst) . . . . . 347  
 transition from proliferative to membranous GN . . . . . 841  
 urine samples . . . . . 182  
 urinary histamine excretion (abst) . . . . . 206  
**Proton magnetic resonance**  
 differentiates ARF (abst) . . . . . 302  
**Proton pumps**  
 clathrin-coated vesicles, ATPase (abst) . . . . . 378  
 Proton, mutant, ATPase (abst) . . . . . 377  
**Proximal convoluted tubules**  
 brushborder membrane vesicles (abst) . . . . . 352  
**Proximal phosphate reabsorption (abst)** . . . . . 155  
**Proximal straight tubule transport**  
 cisplatinum (abst) . . . . . 306  
**Proximal straight tubules**  
 ammonia production by isolated perfused (abst) . . . . . 373  
 protein, uninephrectomy affect volume reabsorption  
 (abst) . . . . . 320  
**Proximal tubular cell**  
 growth occurs at periphery of a colony (abst) . . . . . 402  
 Ca2- mobilizing hormones on brush border topography  
 (abst) . . . . . 160  
 CyA (abst) . . . . . 307  
**Proximal tubular cyst formation (abst)** . . . . . 314  
**Proximal tubular injury**  
 monoclonal antibodies in diagnosing renal disease . . . . . 142  
**Proximal tubule**  
 calcium transport across cortical segment two (abst) . . . . . 155  
 enriched, post ischemic injury (abst) . . . . . 353  
 metabolism and sites of action of vitamin D in kidney . . . . . 98  
 Na+ reabsorption energy requirements . . . . . 32  
 response, immunological injury (abst) . . . . . 267  
 segments, oxidative stress . . . . . 307  
 segments, PL (abst) . . . . . 307  
**Pseudohypoaldosteronism, infant (abst)** . . . . . 943  
**Psychiatric patients**  
 lithium effect on kidney function, serumproteinuria  
 (abst) . . . . . 1255  
**PTH**  
 effects of on renal gluconeogenesis . . . . . 90  
 suppression of, by iron (abst) . . . . . 173  
**Pulmonary diseases, IgA deposition** . . . . . 557  
**Pulmonary edema, acid-base (abst)** . . . . . 197  
**Pulse methylprednisolone therapy (abst)** . . . . . 180  
**Pulse, BP, house officers on call (abst)** . . . . . 253  
**Pump**  
 Na, K-ATPase, structure, function and regulation . . . . . 10  
 reabsorptive K (abst) . . . . . 400  
**Puromycin aminonucleoside (abst)** . . . . . 276  
**PVC tubing in HD, leaching (abst)** . . . . . 217  
**Quin 2 fluorescence, bradykinin (abst)** . . . . . 344  
**Race, allograft survival (abst)** . . . . . 428  
**Radiocontrast agent**  
 diatrizoate precipitates renal tubules, membranes (abst) . . . . . 312  
 diatrizoate (abst) . . . . . 302  
**Radiocontrast agents**  
 GFR decrease (abst) . . . . . 300  
 influence on kidney (abst) . . . . . 309  
 Raffinose, NaCl coefficients (abst) . . . . . 410  
 Ramipril, pharmacokinetics of (abst) . . . . . 241  
 Raw foods, sodium, chloride (abst) . . . . . 262  
**Reabsorption**  
 H2O, HCO3 (abst) . . . . . 372  
 renal Na energy requirements . . . . . 32  
**Receptor, renorenal injury in SHR (abst)** . . . . . 249  
**Red cell morphology in hematuria (abst)** . . . . . 201  
**Rejection**  
 cytomegalovirus glomerulopathy, controversial lesion . . . . . 725  
 interleukin 2 therapy spares T cell (abst) . . . . . 432  
 renal graft, plasmapheresis in treatment (abst) . . . . . 613  
**Rejection, allograft**  
 aminoaciduria in (abst) . . . . . 436  
 characterization of mononuclear cell subsets . . . . . 1043  
 CyA nephrotoxicity, immunohistologic labeling (abst) . . . . . 432  
 cytodiagnostic urinalysis (abst) . . . . . 429  
 HLA-DR antigens (abst) . . . . . 944  
 immunopathology, monoclonal antibodies to mononu-  
 clear cell . . . . . 708  
 leukotriene C4 increase in (abst) . . . . . 332

- magnetic resonance imaging, detects (abst) . . . . . 434  
 MHC unrestricted cytotoxic T lymphocytes (abst) . . . . . 281  
 T4 and T8 cytotoxic lymphocytes in (abst) . . . . . 432  
 urinary thromboxane B2 in diagnosis (abst) . . . . . 1260  
 Relapse, nephrosis (abst) . . . . . 193  
 Relapsing polychondritis (abst) . . . . . 182  
 Remnant glomerulus, PG2 (abst) . . . . . 340  
 Remnant kidney, hypertensive (abst) . . . . . 314  
 Renal  
   involvement in relapsing polychondritis (abst) . . . . . 182  
   kallikrein-kinin system . . . . . 120  
   regulation of function . . . . . 1  
   artery occlusion, surgery (abst) . . . . . 191  
 Renal artery stenosis  
   cerebrovascular disease . . . . . 262  
 Renal biopsy in elderly (abst) . . . . . 204  
 Renal cortex  
   brush border membrane vesicle fraction (abst) . . . . . 352  
 Renal cystic disease  
   accelerated cyst development in deconditioned germ-free rats . . . . . 1116  
 Renal diluting ability (abst) . . . . . 190  
 Renal disease  
   biopsy findings in adolescents (abst) . . . . . 207  
   urinary flow rate influence on protein excretion . . . . . 941  
 Renal failure  
   AIDS-associated (abst) . . . . . 201  
   biliary excretion of conjugated small molecular wt (abst) . . . . . 317  
   biogenesis of hyperparathyroidism (abst) . . . . . 166  
   increase Ca, decrease P in PTX (abst) . . . . . 322  
   morbidity in indigent patients (abst) . . . . . 202  
   plasma chromogranin A in patients with (abst) . . . . . 198  
   transcapillary colloid osmotic gradient, body fluid vol. . . . . 895  
 Renal function  
   altered, mechanism of progressive hepatic congestion (abst) . . . . . 385  
 Renal infection  
   prediction of outcome by chromogenic endotoxin assay (abst) . . . . . 207  
 Renal injury from mercury (abst) . . . . . 199  
 Renal insufficiency  
   ablation, eicosapentaenoic acid (abst) . . . . . 325  
 Renal mass reduction, Ca (abst) . . . . . 321  
 Renal medulla  
   glycerophosphorylcholine (abst) . . . . . 1252  
 Renal papilla  
   comparison of two techniques for x-ray analysis . . . . . 675  
 Renal plasma flow, arginine (abst) . . . . . 190  
   estimated (abst) . . . . . 261  
   response to aldosterone (abst) . . . . . 208  
 Renal scanning by water loading (abst) . . . . . 189  
 Renal sympathetic nerve activity (abst) . . . . . 249  
 Renal tissue  
   platelet activating factor in . . . . . 469  
 Renal vein thrombosis, MRI (abst) . . . . . 206  
 Renalovascular resistance, PGE2 (abst) . . . . . 336  
 Renin  
   antihypertensive treatment in hypertensive rats . . . . . 1011  
   cells transplanted into anterior eye chamber . . . . . 1234  
   endocytosis (abst) . . . . . 255  
   in glomeruli (abst) . . . . . 331  
   kallikrein, immunocytochemical localization in cortex . . . . . 965  
   rapid preparation of protease-free (abst) . . . . . 343  
   release, prostaglandin-stimulated in uninephctomy (abst) . . . . . 381  
   secretion, pertussis toxin in (abst) . . . . . 342  
 Renin-aldosterone system  
   hypertension following coronary artery bypass (abst) . . . . . 263  
 Renin-angiotensin-aldosterone system  
   altered during captopril therapy (abst) . . . . . 257  
 Renorenal reflexes impaired, SHR (abst) . . . . . 249  
 Renotropic effects, indomethacin (abst) . . . . . 339  
 Renovascular resistance, PGE2 (abst) . . . . . 337  
 Respiration  
   ANF, nephron segments (abst) . . . . . 340  
   liganded platinum (abst) . . . . . 309  
   sodium transport, oxygen consumption and ATP . . . . . 3  
 Restless legs syndrome (abst) . . . . . 195  
 Rheumatoid arthritis  
   Cya, Aza in treatment of . . . . . 1180  
   gold nephropathy, detection of autoantibodies to anti-gens . . . . . 539  
 Ribonuclease II isozyme, ARF (abst) . . . . . 305  
 Richard Bright's disease . . . . . 779  
 Rubidium uptake in nephron (abst) . . . . . 391  
 Salt DOCA hypertension, receptor (abst) . . . . . 252  
 Salt, chronic renal injury (abst) . . . . . 244  
 Sarcolemmal vesicles, Na-H (abst) . . . . . 248  
 Scanning electron microscopy GN (abst) . . . . . 282  
 Sclerosis  
   glomerular, interstitial nephropathy, lithium . . . . . 875  
   long-term blood pressure and renal function in donors . . . . . 1072  
 Secondary hyperparathyroidism (abst) . . . . . 317  
 Seiving, glomerular in MGN (abst) . . . . . 390  
 Sepsis, vasoactive hormones (abst) . . . . . 300  
 Serotonin  
   synthesis by renal proximal tubules . . . . . 689  
 Shunting  
   arteriovenous (abst) . . . . . 195  
   arteriovenous, PAVP (abst) . . . . . 346  
 Schwartzman phenomenon, PCA (abst) . . . . . 295  
 Silastic tenckhoff catheter (abst) . . . . . 239  
 Sodium diclofenac, natriuretic (abst) . . . . . 328  
 Sodium  
   acidification activates Na-H exchange, Na-K pump (abst) . . . . . 397  
   aldosterone induced, glucocorticoids (abst) . . . . . 330  
   ATPases, classes, distribution and function of . . . . . 21  
   calcium exchange system of basolateral membranes (abst) . . . . . 425  
   channel, modification in frog skin epithelium (abst) . . . . . 400  
   chronic loading, angiotensin II, adenosine (abst) . . . . . 385  
   cotransport with glucose . . . . . 54  
   cyclosporine treatment (abst) . . . . . 304  
   dependent aldosterone stimulation of CCD (abst) . . . . . 397  
   effect of acid medium pH on (abst) . . . . . 164  
   energy requirements for reabsorption . . . . . 32  
   epithelial, solubilization of channel (abst) . . . . . 400  
   excretion during volume expansion, ANP (abst) . . . . . 407  
   excretion in IEPK, ADH and PGE2 (abst) . . . . . 401  
   excretion, dietary potassium as determinant (abst) . . . . . 182  
   furosemide sensitive, uremic plasma (abst) . . . . . 316  
   H<sup>+</sup> antiport inhibition by sulfated bile acid (abst) . . . . . 1257  
   high, plasma levels of ANF and ouabain factor (abst) . . . . . 404  
   homeostasis, atrial natriuretic factor determinations and . . . . . 1004  
   hyperglycemia induces retention (abst) . . . . . 417  
   hypernatremia inhibits NaHCO<sub>3</sub> reabsorption . . . . . 820

- inhibits H-driven Na-H exchange (abst) ..... 397  
 K-ATPase in the kidney ..... 10  
 MNR measures in proximal tubules, diabetic (abst) .... 356  
 Na-H antiport activity of exchanger (abst) ..... 396  
 Na-H exchange is pathway for influx (abst) ..... 401  
 Na/H antiporter, ammonium on (abst) ..... 402  
 not visible in proximal tubules Tal (abst) ..... 392  
 PGE2 synthesis of (abst) ..... 405  
 plasma concentrations, hospital-associated  
   hyponatremia ..... 1237  
 pump in salt gland, gut tubes of brine shrimp (abst) ... 394  
 regulation of renal acid secretion in distal nephron segment ..... 1099  
 restriction moderates hypertension (abst) ..... 254  
 restriction, ACE-inhibition and hypertension (abst) ... 945  
 restriction, role of renal nerves in adaptation (abst) ... 253  
 retention in nephrotic syndrome, aldosterone (abst) ... 203  
 retention, role of aldosterone-independent tubular (abst) ..... 260  
 reversible modification of channel (abst) ..... 1255  
 saline volume expansion, ANP levels during (abst) .... 406  
 single channel events in apical membrane of CCD (abst) ..... 397  
 single channels in apical membrane of CCT (abst) ..... 404  
 transition from proliferative to membranous GLN .... 841  
 transport in papillary collecting tubule (abst) ..... 401  
 transport in red blood cells from dialyzed uremic .... 1197  
 transport, apical, entry into ambystoma (abst) ..... 403  
 transport, CGMP and atriopeptin effect on (abst) ..... 331  
 transport, oxygen consumption and ATP ..... 3  
 uptake by papillary collecting duct cells (abst) ..... 399  
 washout, angiotensin II from VSMCs (abst) ..... 338  
 x-ray microprobe technique in finding ..... 682  
<sup>23</sup>Na NMR spectroscopy of proximal tubule suspensions ..... 747  
 Sodium-calcium exchange, PTH (abst) ..... 171  
 Solubility of aluminum ..... S-3  
 Somatostatin 14, 28 (abst) ..... 358  
 Somatostatin, AVP cAMP in MDCK (abst) ..... 416  
 Sorbitol, renal papillary cells (abst) ..... 412  
 Spatial reconstructor, blood flow (abst) ..... 380  
 Spectroscopy, NMR in renal biochemistry ..... 131  
 Sphingolipids, dexamethasone (abst) ..... 334  
 Steady-state  
   IP3 on rat kidney cortex ..... 695  
 Stenosis, renal artery, ERPF scan (abst) ..... 261  
 Steroid metabolism in PKD (abst) ..... 271  
 Steroid pulse therapy, MGN ..... 927  
 Steroid, hypertensinogenic 19-NOR (abst) ..... 253  
 Steroids  
   SECO, Ca-dependent K channels inactivated by (abst) . 158  
 Stone formers  
   nephrolithiasis ..... 563  
   nonstruvite (abst) ..... 194  
 Stones, renal  
   isolation of glycoprotein crystal growth inhibitor (abst) . 167  
 Streptococcus mutans perfusion (abst) ..... 264  
 Streptozotocin diabetic, indomethacin ..... 490  
 Streptozotocin, ARF (abst) ..... 301  
 Stress management for ESRD (abst) ..... 201  
 Strip test, specific gravity (abst) ..... 177  
 Struvite stone disease (abst) ..... 170, 194  
 Submitochondrial particles  
   glutamine transport in (abst) ..... 359  
 Substrate  
   metabolic fuels along the nephron ..... 41  
 Suckling, effects blood pressure (abst) ..... 241  
 Sulfidopeptide leukotriene (abst) ..... 346  
 Sulfur  
   mediation in bone and PTH inhibitory action of WR2721 (abst) ..... 159  
 Sulindac sulfide during hemorrhage ..... 484  
 Superoxide stimulation (abst) ..... 268  
 Suppressor cell  
   activity factor (abst) ..... 289  
   in transfusions (abst) ..... 427  
   induction, T cell (abst) ..... 428  
 Suppressor factor, lymphocyte (abst) ..... 432  
 Survival, allograft, by race (abst) ..... 428  
 Symptomatic hyponatremia (abst) ..... 205  
 Synovial amyloid deposits (abst) ..... 229  
 Systemic edema, SCLS (abst) ..... 181  
 Systemic illness, hypernatremia (abst) ..... 204  
 Systemic lupus erythematosus  
   (abst) ..... 273, 276  
   children ..... 1066  
   CyA (abst) ..... 294  
   glomerulonephritis in ANF negative (abst) ..... 1256  
   study (abst) ..... 287  
 Systems, PGE2, BP, AII (abst) ..... 346  
 T cell  
   interleukin-2 mitogenic to peripheral blood (abst) ..... 286  
   interstitial nephritis (abst) ..... 286  
   mononuclear cell marker, renal allograft rejection .... 708  
   new model (abst) ..... 436  
   suppressor cell activity maintenance factor (abst) .... 289  
   interleukin 2 receptor therapy spares (abst) ..... 432  
   performance of suppressor (abst) ..... 433  
   splenic (abst) ..... 428  
   suppressor, contrasuppressor in SIN (abst) ..... 280  
   1-J+ suppressor, interstitial nephritis (abst) ..... 284  
 T lymphocytes in hybrid molecule (abst) ..... 270  
 Tamm-Horsfall  
   biochemistry of protein in diabetes mellitus (abst) .... 1257  
   characterization of monoclonal antibodies specific for .. 971  
   crystal growth inhibitor, albumin (abst) ..... 295  
   urinary calcium oxalate crystal growth inhibitor ..... 829  
 Terminal complement components  
   hypertensive glomerular injury (abst) ..... 274  
 Theophylline in ARF (abst) ..... 308  
 Theophylline-induced protect ARF (abst) ..... 299  
 Thrombotic microangiopathy (abst) ..... 280  
 Thromboxane  
   A2 in glycerol-induced ARF (abst) ..... 1257  
   A2, glucose reabsorption increased (abst) ..... 330  
   B2, in diagnosis of allograft rejection (abst) ..... 1260  
   B2 formation in GN (abst) ..... 1250  
   endoperoxide, mesangial cells (abst) ..... 340  
   in hypertension (abst) ..... 227  
   in nephrectomy (abst) ..... 329  
   prostaglandin production, protein (abst) ..... 336  
   synthetase inhibition (abst) ..... 777  
   synthesis inhibition of proteinuria, GFR (abst) ..... 347  
 Thromboxytosis, progressive  
   chronic peritoneal dialysis associated with (abst) ..... 240  
 Thyroid  
   ablation, glomerular (abst) ..... 318  
   hormone, uremia (abst) ..... 322



- parathyroidectomy in rabbits (abst) . . . . . 161
- Thyrotoxicosis, ADH, Type B Syn (abst) . . . . . 421
- Thyroxine, fluid balance in DOCA (abst) . . . . . 243
- Tobramycin, toxicity (abst) . . . . . 313
- Torsemide (abst) . . . . . 1254
- Total body irradiation  
prior to bone marrow transplantation (abst) . . . . . 206
- Toxicity  
aluminum in CHD (abst) . . . . . 211  
aluminum-induced bone disease . . . . . S-32  
aluminum, with experimental renal failure (abst) . . . . . 175  
Bence Jones protein (abst) . . . . . 309  
calcium to renal medulla (abst) . . . . . 298  
cyclosporine A, intraluminal obstruction (abst) . . . . . 312  
gentamicin, bacteremia (abst) . . . . . 313  
gold nephropathy, detection of autoantibodies to anti-  
gens . . . . . 539  
phosphate binding gels balance adsorption, Al . . . . . 1131  
role of plasma aluminum in detection, prevention of . . . . . S-91  
tobramycin dosing (abst) . . . . . 313  
WR-2721 protects against cisplatin (abst) . . . . . 311  
2-bromohydroquinone, glutathione (abst) . . . . . 310
- Toxin  
aluminum-related bone disease . . . . . S-80
- Transdermal clonidine in RI (abst) . . . . . 251
- Transfusion  
donor specific, suppressor cells (abst) . . . . . 427
- Transluminal angioplasty in renal (abst) . . . . . 191
- Transplantation  
anencephalic neonate donor (abst) . . . . . 430  
blood pressure in donor, recipient (abst) . . . . . 436  
blood transfusions and cyclosporine (abst) . . . . . 435  
cadaveric renal without dialysis, in ESRD (abst) . . . . . 942  
cardiovascular rehabilitation after renal (abst) . . . . . 1263  
CMV-prophylaxis (abst) . . . . . 1262  
convert from CyA to azathioprine improves function  
(abst) . . . . . 433  
coronary revascularization, valvular procedure (abst) . . . . . 427  
corpulence-index in CyA dosage (abst) . . . . . 1262  
cryoprotective dimethyl sulfoxide perfusion (abst) . . . . . 431  
Cya, Aza in allografts with severely impaired function  
(abst) . . . . . 1261  
cyclosporin in cadaveric renal (abst) . . . . . 612  
cyclosporine conversion in stable (abst) . . . . . 437  
cyclosporine therapy convert to azathioprine (abst) . . . . . 435  
exercise, cardiovascular responses to (abst) . . . . . 434  
expression of HLA-DR, DP, DQ antigens (abst) . . . . . 1261  
familial glomerulopathy, giant fibrillar deposits (abst) . . . . . 1262  
fine needle biopsy in kidney (abst) . . . . . 430  
GFR in CyA treated (abst) . . . . . 428  
hematopoiesis following (abst) . . . . . 427  
hepatic veno-occlusive disease (abst) . . . . . 435  
HLA-A, B compatible blood transfusion (abst) . . . . . 612  
influenza vaccination in hemodialysis and renal (abst) . . . . . 942  
instrumented conscious dogs, CyA (abst) . . . . . 1262  
light chain nephropathy (abst) . . . . . 943  
living nonrelated donor (abst) . . . . . 430  
kidney cells into anterior eye chamber . . . . . 1234  
magnetic resonance imaging, loss of demarcation (abst) . . . . . 429  
membranoproliferative glomerulonephritis in (abst) . . . . . 429  
mononuclear subsets monitor CMV infection in renal  
(abst) . . . . . 944  
polycystic kidney disease (abst) . . . . . 437  
primary renal (abst) . . . . . 430  
rejecting, cyclosporine rescues (abst) . . . . . 426
- renal biopsy and fine-needle biopsy in (abst) . . . . . 612
- serum urate levels and cyclosporine (abst) . . . . . 426
- survival, risk factors in 600 grafts (abst) . . . . . 434
- T cell activation, new model (abst) . . . . . 436
- Transport  
adenosine, theophylline and papaverine effect (abst) . . . . . 332  
aldosterone induces chloride (abst) . . . . . 1229  
alkalosis on phosphate, in renal proximal tubule (abst) . . . . . 163  
amiloride on renal MG handling in distal tubule (abst) . . . . . 163  
ammonia in medullary collecting tubule (abst) . . . . . 367  
and metabolic functions in cultured renal tubule cell . . . . . 46  
apical membrane, Na entry in ambystoma tubule (abst) . . . . . 403  
ATP, Na-K-ATPase activity, luminal active (abst) . . . . . 611  
ATPase in tubular electrolyte . . . . . 21  
calcium, across cortical segment two proximal tubules  
(abst) . . . . . 155  
calcium, PTH in uremia effect on (abst) . . . . . 158  
Ca<sup>2+</sup>, PTH stimulates (abst) . . . . . 421  
cephalosporin (cefodizim) (abst) . . . . . 1256  
chloride, pathways in CCT (abst) . . . . . 409  
co-electrogenic Na/HCO<sub>3</sub> in necturus proximal tu-  
bules (abst) . . . . . 371  
co-, NaHCO<sub>3</sub> in BLMV (abst) . . . . . 362  
control of cell pH in BLM (abst) . . . . . 362  
cystine, change in characteristics (abst) . . . . . 350  
dependent cell injury in S3 segment . . . . . 1033  
effects of phosphate (Pi) on (abst) . . . . . 171  
epithelial inorganic phosphate (abst) . . . . . 172  
glutamine in renal submitochondrial particles (abst) . . . . . 359  
H<sup>+</sup>/OH<sup>-</sup>, renal brush border (abst) . . . . . 378  
high K diet on CCD of adrenalectomized rabbit (abst) . . . . . 403  
inhibition of phosphate by phosphonocarboxylic acids  
(abst) . . . . . 164  
inhibitor, produced by mTAL (abst) . . . . . 351  
inorganic sulfate (abst) . . . . . 1254  
inositol triphosphate-sensitive calcium pool (abst) . . . . . 157  
insulin, luminal uptake and intracellular . . . . . 983  
ion, fusion of renal epithelial cells (abst) . . . . . 404  
K and ammonia in turtle bladder (abst) . . . . . 377  
K depletion effect on HCO<sub>3</sub> (abst) . . . . . 368  
luminal uptake and intracellular, of insulin . . . . . 983  
luminal, basolateral lactate, pH in tubules (abst) . . . . . 376  
metabolism of dipeptides (abst) . . . . . 1252  
Na or membrane lipid events, dietary amino acid (abst) . . . . . 413  
Na-dependent acetate on pH (abst) . . . . . 373  
Na-HCO<sub>3</sub> in BLMV (abst) . . . . . 367  
Na<sup>+</sup> channel modification in frog skin epithelium  
(abst) . . . . . 400  
Na<sup>+</sup> reabsorption, energy requirements . . . . . 32  
Na,K-ATPase structure, function and regulation in the  
kidney . . . . . 10  
NaCl, formate stimulates active (abst) . . . . . 407  
nucleosides in brush border vesicles (abst) . . . . . 1253  
N1-methylnicotinamide in proximal renal tubules (abst) . . . . . 414  
osmotic water in tubule cells in suspension (abst) . . . . . 421  
oxalate, method of (abst) . . . . . 161  
PAH reabsorption (abst) . . . . . 371  
paraaminohippurate kinetics (abst) . . . . . 424  
parallel antiporters, NaCl in PCT (abst) . . . . . 390  
peritoneal by captopril (abst) . . . . . 233  
peritoneal in CAPD patients (abst) . . . . . 941  
peritoneal, dual barrier model of (abst) . . . . . 234  
phosphate, heterogeneity of sodium-dependent (abst) . . . . . 169  
phosphate, nicotinamide inhibits (abst) . . . . . 161  
phosphate, phosphonocarboxylic acids inhibit (abst) . . . . . 172

- phosphonocarboxylic acids inhibit Na<sup>+</sup> dependent (abst) ..... 172
- physiological characteristics, symposium ..... 1
- regulation of Na, K by adrenal corticosteroids (abst) .. 407
- renal glucocorticoid metabolites on membrane (abst) ... 358
- renal tubular support by glucose ..... 54
- role of loop segment in hypercalcemia ..... 977
- sodium, cGMP and atriopeptin II effect on (abst) ..... 331
- sodium, in red blood cells from dialyzed uremic patients ..... 1197
- sodium, in renal papillary collecting tubule (abst) ..... 401
- sodium, potassium activity (abst) ..... 392
- sodium, relationship of renal ATP to (abst) ..... 359
- sugar co-, in LLC-PK1 (abst) ..... 419
- tetraethylammonium and morphine (abst) ..... 423
- TPA stimulates Na-dependent phosphate in (abst) ..... 167
- transepithelial ammonia in proximal straight tubule (abst) ..... 366
- two sodium-dependent glucose, in small intestine (abst) .. 423
- urate, uricase as carrier (abst) ..... 422
- vitamin D stimulates phosphatidylcholine transfer (abst) ..... 162
- Travenol, reduction peritonitis (abst) ..... 240
- Treatment of ESDR by state (abst) ..... 201
- Tripeptide
- glutathione depletors, proximal tubules ..... 858
- Tripletherapy
- effects of antihypertensive treatment in hypertensive rats ..... 1011
- Tubular
- basement membrane component change in PKD (abst) . 268
- changes during PKD (abst) ..... 320
- dysfunction, alcohol-associated nephropathy (abst) .... 609
- reabsorption, aldosterone-independent (abst) ..... 260
- transport function ..... 1
- Tubule
- acidification in medullary collecting duct ..... 1167
- ambystoma proximal, transport on cell pH (abst) ..... 376
- ammonia production, isolated perfused proximal (abst) . 373
- ammonia transport in medullary collecting (abst) ..... 367
- amphiuma, K and CL<sup>+</sup> channels in membrane (abst) .. 399
- atrial extract, atriopeptin III (abst) ..... 401
- atrial natriuretic factor, intrarenal effects (abst) ..... 408
- Ca, nephron segment as determinants of anoxic cell death ..... 11
- cell pH in, luminal HCO<sub>3</sub><sup>-</sup> (abst) ..... 374
- cortical collecting, Na channels in apical membrane (abst) ..... 404
- cortical collecting, Cl secretion on diet (abst) ..... 410
- cortical collecting, basolateral amiloride (abst) ..... 371
- cortical collecting, immunodissection and culture (abst) .. 424
- cortical suspensions, norepinephrine, Na-K ATPase (abst) ..... 391
- distal cell types, monoclonal antibodies (abst) ..... 360
- distal, bicarbonate reabsorption is load-dependant (abst) ..... 365
- early distal convoluted, basolateral K conductance (abst) ..... 409
- electrophysiological characteristics of (abst) ..... 391
- functions during hypotonic volume expansion (abst) .. 420
- glucagon in man, effects of (abst) ..... 413
- glutathione depletors on proximal ..... 858
- hypotonicity, K, Na, Cl in renal proximal (abst) ..... 406
- hypoxic injury in proximal ..... 1021
- indomethacin secretion by PST (abst) ..... 414
- inhibitory effect of atrial natriuretic peptide (abst) ..... 425
- isolated cortical collecting, vasopressin (abst) ..... 419
- isolated perfused PST, phorbol ester (abst) ..... 411
- isolated renal, glomerular preparation (abst) ..... 352
- lithium renal lesions ..... 875
- luminal uptake and intracellular transport of insulin ... 983
- method to get a suspension enriched in proximal (abst) . 611
- mid-cortical collecting, intercalated cell difference (abst) ..... 375
- osmotic water transport (abst) ..... 421
- paired responses to osmolar raffinose and NaCl (abst) .. 410
- proximal BBM, ATPase activity (abst) ..... 368
- proximal cells, x-ray analysis ..... 682
- proximal convoluted, dopamine on NaKATPase activity (abst) ..... 390
- proximal convoluted, H<sub>2</sub>O permeability on gradient (abst) ..... 412
- proximal convoluted, luminal and peritubular pH (abst) .. 413
- proximal convoluted, norepinephrine mechanism (abst) . 394
- proximal, acid-base disturbance, HCO<sub>3</sub><sup>-</sup> (abst) ..... 375
- proximal, CO<sub>2</sub> stimulates growth (abst) ..... 363
- proximal, hypernatremia inhibits NaHCO<sub>3</sub> reabsorption ..... 820
- proximal snake, N1-methylnicotinamide in (abst) ..... 414
- PTH dependent phosphorylation of proteins in (abst) .. 167
- regulation of renal acid secretion ..... 1099
- renal proximal, pathway for serotonin ..... 689
- systemic acidosis (abst) ..... 368
- S2, anisotonic media regulation (abst) ..... 419
- thick ascending limb, sodium, NMR (abst) ..... 392
- transport of K and Na in PCT (abst) ..... 392
- transport-dependent cell injury in S3 segment ..... 1033
- tubulopathy in nephrolithiasis ..... 563
- <sup>23</sup>Na NMR spectroscopy of proximal, suspensions .... 747
- Tubuloglomerular feedback
- acute volume expansion (abst) ..... 388
- control of GFR (abst) ..... 388
- increase in GFR during volume expansion (abst) ..... 1253
- Tubulopathy in nephrolithiasis ..... 563
- Ultrafiltration
- maximum on peritoneal dialysis (abst) ..... 235
- remission induced by, NS and FGS (abst) ..... 776
- transcapillary colloid osmotic gradient, body fluid volumes ..... 895
- Uninephrectomy
- response of plasma 1,25(OH)<sub>2</sub>D to PTH (abst) ..... 158
- Urea formation, acid-base (abst) ..... 367
- Uremia
- aluminum metabolism ..... S-8
- associated hyporesponsiveness to thyroid hormone (abst) ..... 322
- calcium carbonate, Al-free agent for control ..... S-114
- diminishes 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors (abst) ..... 170
- effect of aluminum on PTH secretion ..... S-41
- effect of 1,25(OH)<sub>2</sub>D<sub>3</sub> on zinc absorption (abst) ..... 154
- epitrochlearis muscle, insulin (abst) ..... 316
- hematopoietic inhibitors in chronic renal failure ..... 641
- low protein-essential amino acid diet, risk and benefits . 995
- mouse model (abst) ..... 318
- phosphate restriction and CRF ..... 658
- plasma phospholipase A2 activity (abst) ..... 316
- PTH effects on calcium transport in brain (abst) ..... 158
- skeletal resistance to PTH in (abst) ..... 319
- zinc balances of (abst) ..... 321

- 99mTc-methylene diphosphonate bone scan in osteo-dystrophy ..... 1058
- Uremic
- adrenalectomy, protein in (abst) ..... 309
  - alpha-ketoisocaproate for protein synthesis (abst) ..... 326
  - calcium transport (abst) ..... 315
  - dialysis encephalopathy ..... S-53
  - enhanced gastrointestinal adsorption of Al in (abst) ... 1260
  - hemolytic syndrome, oral contraceptives (abst) ..... 777
  - methods for aluminum measurement ..... S-24
  - nitrogen metabolism, energy intake, in CRF ..... 734
  - pericarditis in diabetics (abst) ..... 186
  - plasma, Na<sup>+</sup> efflux (abst) ..... 316
  - protein synthesis and degradation in skeletal muscle .. 1136
  - serum, calcium oxalate (abst) ..... 315
  - serum and spinal fluid aluminum levels in (abst) ..... 211
  - sodium transport in red blood cells from dialyzed .... 1197
  - symptoms at start of chronic hemodialysis (abst) ..... 176
- Ureteral ligation, bilateral
- elimination of plasticizer DI-2-(ethylhexyl) ..... 214
- Ureteric ligation, histology (abst) ..... 296
- Ureteropelvic junction obstruction
- separate renal function in children (abst) ..... 200
- Uricase
- for urate transport (abst) ..... 422
  - in isolated membrane (abst) ..... 411
- Urinalysis
- cytodiagnostic (abst) ..... 429
  - survey (abst) ..... 184
- Urinary
- doubly refractile lipid bodies in NGRD (abst) ..... 180
  - erythrocyte morphology, excretion, IgA nephropathy (abst) ..... 181
  - protein excretion, teenagers (abst) ..... 191
  - thromboxane, cyclosporin nephrotoxicity (abst) ..... 304
  - tract anomalies, lasix renography for diagnostic (abst) .. 208
  - tract obstruction, changes in renal metabolism ..... 80
- Urine
- anion gap, diagnostic tool (abst) ..... 188
  - assessment of urinary chloride (abst) ..... 186
  - atrial natriuretic factor inhibition of AVP (abst) ..... 328
  - blood PCO<sub>2</sub> gradient in bicarbonate diuresis (abst) .... 373
  - calcium and calcium intake relationship during calcitriol ..... 578
  - characterization of monoclonal antibodies for Tamm-Horsfall ..... 971
  - concentrating ability, hypercalcemia, role of loop segment ..... 977
  - diagnostic value of erythrocyte morphology in (abst) .. 1258
  - excretion, circadian variations in nephrotic syndrome (abst) ..... 942
  - excretion, colloid volume expansion on glomerular barrier ..... 916
  - flow rate influence on protein excretion (abst) ..... 941
  - hypercalcemia on concentrating ability (abst) ..... 423
  - osmolality, leukotrienes (abst) ..... 335
  - plasma ANF levels following infusion (abst) ..... 409
  - procoagulant activity associated with subcellular particles ..... 591
  - proteinuria and oxygen free radicals ..... 478
  - samples in assessment of proteinuria (abst) ..... 182
  - sodium excretion, ANF ..... 1004
  - anion gap, diagnostic tool (abst) ..... 188
- Urokinase
- i.v. (abst) ..... 223
  - phospholipase D (abst) ..... 344
  - restores catheter (abst) ..... 235
- Urolithiasis, tubulopathy ..... 563
- Uropathy
- congenital obstructive (abst) ..... 331
  - obstructive, acidification ..... 1167
- Validation of method
- atomic absorption spectroscopy to detect aluminum... S-28
- Valproate stimulation of ammonia (abst) ..... 350
- Vanadate
- acidification (abst) ..... 364
  - ouabain (abst) ..... 330
  - PO<sub>4</sub> clearance (abst) ..... 425
- Vancomycin clearances in HD (abst) ..... 228
- Vasa recta blood flow, V2 (abst) ..... 418
- Vascular
- a-adrenoceptor, assess (abst) ..... 244
  - abberancies of ARF (abst) ..... 299
  - effects of acetate (abst) ..... 218
  - diameter response to angiotensin II (abst) ..... 381
  - hemodynamic effect of atrial natriuretic peptide (abst) .. 383
  - hemodynamics during infusion of amino acids, dopamine ..... 870
  - L-platelet activating factor changes RVR (abst) ..... 388
  - recirculation rate, HD (abst) ..... 219
  - smooth muscle, Na-H ..... 248
- Vasoconstrictor
- ANP-induced (abst) ..... 245
  - serotonin synthesis by proximal tubules ..... 689
- Vasodilation, renal
- arterial pressures in dog (abst) ..... 380
  - therapy, hypertension (abst) ..... 175
- Vasomotor response, AII (abst) ..... 610
- Vasopressin
- adenylate cyclase activity, protein kinase C (abst) ..... 415
  - activation of system, a pathway for pressor agents (abst) ..... 246
  - antagonist prevents hyponatremia (abst) ..... 418
  - AVP-induced cAMP accumulation in MDCK (abst) ..... 416
  - calcium in mobilization of (abst) ..... 415
  - captopril through PGE<sub>2</sub> production, cAMP generation (abst) ..... 420
  - clinical hyponatremia (abst) ..... 1258
  - hospital-associated hyponatremia ..... 1237
  - increased urinary excretion of PGE<sub>2</sub> during antidiuresis ..... 1110
  - inhibition of permeability after repeated (abst) ..... 419
  - modulation of plasma, platelet, by cardiac function ... 1188
  - phosphatidyl inositol 4,5 bisphosphate hydrolysis (abst) .. 422
  - renin-angiotensin system in congestive heart failure (abst) ..... 193
  - stimulated cAMP formation by increased Ca (abst) .... 425
  - V2 receptor, GTP-binding proteins (abst) ..... 424
- Ventilation
- acetate vs. bicarbonate dialysis in (abst) ..... 944
  - positive end expiratory pressure ventilation (abst) ..... 415
- Verapamil
- aminoglycoside-induced ARF (abst) ..... 312
  - atriopeptin III on renal function after ischemia (abst) .. 943
  - chronic renal failure (abst) ..... 319
  - induced natriuresis in CVAL dogs (abst) ..... 382
  - modulates hormonal action ..... 863
  - protective effect of on bone resorption (abst) ..... 156



- Vesicles**  
  medullary, chloride channel in bovine kidney (abst) . . . 398  
**Veterinary, canine chronic renal disease** . . . 1144  
**Vitamin B6 deficiency (abst)** . . . 228  
**Vitamin D**  
  abnormal in hypertensive (abst) . . . 247  
  Al binding protein (abst) . . . 154  
  metabolism and sites of action in the kidney . . . 98  
  regulation of intestinal phosphate absorption (abst) . . . 163  
**Vitamin D3**  
  inhibitory effect on growth of renal carcinoma cell line . 834  
**Vitamin E**  
  gentamicin induced lipid peroxidation (abst) . . . 303  
**Volume**  
  inorganic sulfate transport (abst) . . . 1253
- Water**  
  Australian municipal supplies, aluminum contamination . S-65  
  restriction, humoral control of water, electrolyte excretion . . . 1152  
  soft vs. hard in Ca stone formers (abst) . . . 778  
  intake, angiotensin II (abst) . . . 1252  
  loading, renal scanning (abst) . . . 189  
  treatment in Newcastle disease . . . S-58  
**Wegener's granulomatosis (abst)** . . . 185  
**Western-blot technique, antigens (abst)** . . . 1116  
**WR-2721**  
  PTH secretion suppression by (abst) . . . 174  
  sulfur group activity mediates bone and PTH action (abst) . . . 159
- X-ray**  
  comparison of two techniques for analysis, renal papilla . . . 675  
  microprobe techniques for analysis of proximal tubule cells . . . 682
- Zinc**  
  absorption in uremia (abst) . . . 154  
  balances uremic (abst) . . . 321  
  metabolism in CAPD (abst) . . . 234
- 1,25(OH)2D3**  
  and bone GLA decrease and parathyroidectomy (abst) . 186  
  compensatory renal growth, modulation by Ca PTH and . . . 1124  
  evidence for an endogenous receptor activator (abst) . . 156  
  immunomodulation (abst) . . . 265  
  inhibitory effect on growth of renal carcinoma cell line . 834  
  intestinal calcium absorption in hypertensive (abst) . . . 159  
  PTH, effects of on intestinal and renal Al handling (abst) . . . 173  
  reduced in hypertensive rat (abst) . . . 165  
  regulation by, of pre-proparathyroid hormone mRNA (abst) . . . 172  
  stimulates interleukin\_2 production (abst) . . . 160  
  synthesis of in proximal tubules (abst) . . . 162  
  uremia diminishes receptors (abst) . . . 170  
  12-hydroxyicosatetraenoic acid (abst) . . . 335  
  125I iothalamate clearance, GFR (abst) . . . 188  
  31P-NMR, hypoxia (abst) . . . 358  
  6-thiouric acid, AZA (abst) . . . 437